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”Knowledge without follow-through is worse than no knowledge at all. because if you're 
guessing and it doesn't work out you can just say, shit, the gods are against me. but if you 
know and don't do, you've got attics and dark halls in your mind to walk up and down in and 
wonder about. this ain't healthy, leads to unpleasant evenings, too much to drink and the 
shredding machine.” 
Charles Bukowski 
 
 
 
 
 
 
  
ABSTRACT 
Introduction: Prostate cancer is the most common form of cancer among men in Sweden. 
There has been a rapid increase in the incidence rate of prostate cancer following the 
introduction of PSA testing and, today, more than 1800 men are diagnosed with the disease 
annually in Stockholm, Sweden. This increased testing has, however, not led to any 
significant reduction in the mortality of prostate cancer. There is no official screening 
programme for prostate cancer in Sweden, however, more than 60% of men above the age of 
60 have undergone a PSA test in the last 5 years. What is less known is what proportion of 
men undergo a prostate biopsy after a PSA test and within what time frame. The majority of 
men undergoing a prostate biopsy are not diagnosed with a prostate cancer. In a setting where 
the PSA test had a better specificity these men would not have to undergo a prostate biopsy. 
To perform a prostate biopsy is not without risks. Serious infectious complications following 
prostate biopsies have been reported to be increasing in other parts of the world. The serious 
infectious complication rate in Stockholm, following a prostate biopsy, is not known. 
Aims: To investigate if genetic markers, SNPs, can be used as a complement to PSA to 
predict which men with a PSA <10 ng/mL need to undergo prostate biopsies. To explore the 
prostate biopsy rates and results in Stockholm and to investigate when PSA testing leads to 
prostate biopsies and to what extent these prostate biopsies cause side effects in terms of 
severe infections. 
Material and Methods: In Study I, 8088 men were identified who underwent at least one 
prostate biopsy in Stockholm between 2005 and 2007. Those alive and younger than 80 years 
of age, were invited to donate blood and fill out a questionnaire. 2542 men were included in 
the analysis when restricted to age less than 80, alive at time of invitation, valid PIN, and a 
PSA <10 ng/mL. In Study II, 860 men aged 50 to 69 years with a PSA of 1-3 ng/mL without 
a history of prostate cancer or previous prostate biopsies were invited to undergo a prostate 
biopsy. 172 men were stratified into low-, intermediate- and high-risk groups according to 
their genetic score and then underwent a prostate biopsy. In Studies I and II, a genetic score, 
based on the known SNPs associated with a risk of prostate cancer at the time of the study in 
combination with PSA and other predictive factors, was created and used in a prediction 
model to enhance specificity in men with a PSA<10 ng/mL and sensitivity in men with a 
PSA of 1-3 ng/mL. In Study III, men who had undergone at least one prostate biopsy in 
Stockholm from 2003 to 2012 were included. Biopsies done in 2003 were acknowledged but 
not included in the analysis. Migration data was used for population analysis. Data from 38 
800 biopsies was analysed. Main outcome in the study was time from PSA test to prostate 
  
biopsy. In Study IV, prostate biopsies (n=44 047) done from 2003 to 2012 were included and 
linked by the use of PIN to microbiological data resources to identify blood cultures taken 
and available biograms. The main variable studied for outcome was year of biopsy. Logistic 
regression and time to event were used to address associations. The net reclassification index 
was used to evaluate the predictive performance of the genetic risk score. In all the studies 
men were linked to several health registers, such as the Swedish Cancer Register, the 
National Prostate Cancer Register, the Swedish Cause of Death Register, the National Patient 
Register, and the Total Population Register. 
Results: In Study I, up to 23% of the prostate biopsies could have been avoided by using a 
genetic risk score in combination with age, family history, PSA and f/t PSA. The proportion 
of missed cancers would be between 5.8 and 12% depending on the risk cut-off used. The 
proportion of aggressive cancers missed would be between 3.3 and 8.3%. In Study II, the 
proportion of cancers diagnosed in the low-, intermediate- and high-risk groups was 18, 28 
and 37 %, respectively (p<0.05). A borderline significant trend was seen between a higher 
genetic risk score and the risk of an aggressive prostate cancer. In Study III, 58 and 45% of 
men in aged 50-59 and 60-69 years of age, respectively, with a PSA between 4 and 10 ng/mL 
underwent a prostate biopsy within one year of the PSA test. For men with a PSA >10 ng/mL 
the proportion was 67 and 58% respectively. One out of eight men with an advanced prostate 
cancer had a first known PSA of  >4 ng/mL more than 6 months prior to their diagnosis. In 
Study IV, the proportion of men with a positive blood culture within 30 days of the prostate 
biopsy in 2003 was 0.38 and 1.14% in 2012. Year of biopsy was highly significant as a risk 
factor for undergoing a blood culture and was robust both in the simple - and the adjusted 
analysis. Young age and low PSA values were associated with a risk of undergoing a blood 
culture. Men with a high Charlson Comorbidity Index had an increased risk of undergoing a 
blood culture. Bacteria resistant to common prophylactic antibiotics were more frequently 
found in blood cultures in the later years of the study than in the early years. 
Conclusion: A genetic risk score can be used to enhance the sensitivity and specificity of 
PSA in men undergoing an investigation for prostate cancer. By reducing the number of 
unnecessary biopsies the number of men suffering from severe infectious complications will 
be reduced as well as the number diagnosed with a low-risk prostate cancer. The proportion 
of relatively young men not undergoing a prostate biopsy within one year of the PSA test, 
although their result was pathological, was surprisingly high. One way to solve this problem 
would be to introduce a structured follow-up after PSA testing.  
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1 OVERVIEW OF THESIS 
 
 Aim Subjects and Methods Results and Conclusion 
I 
To investigate if a 
genetic risk score 
based on SNPs can be 
used in a prediction 
model to avoid 
unnecessary prostate 
biopsies. 
Men in Stockholm who had 
undergone a first known prostate 
biopsy from 2005 to 2007 with a 
PSA <10 ng/mL. 
 
 
Logistic regression and 
prediction. NRI. 
Using a genetic model, 12 to 23% of the 
prostate biopsies would be avoided, 6-
12% of cancers would be missed, and 
3.3-8.3% of the aggressive cancers 
would be missed. 
 
A genetic risk score can be used to 
avoid unnecessary prostate biopsies in 
men with moderately elevated PSA. 
 
II 
To investigate if a 
genetic risk score 
based on SNPs can be 
used to identify men 
with a high risk of 
prostate cancer 
although their PSA is 
low. 
Men, aged 50-69 years, in 
Stockholm with no prior history 
of prostate biopsies and prostate 
cancer with a PSA of 1-3 ng/mL. 
 
10-12 core biopsies were done 
using ultrasound-guided 
technique. 
 
Logistic regression analysis, 
NRI. 
Prostate cancer was detected in 27% of 
the 172 men undergoing a prostate 
biopsy. Stratified by their genetic risk, 
prostate cancer was found in 18, 28 and 
37% of men with a low, intermediate 
and high genetic risk score, respectively. 
 
 
A genetic risk score can be used to 
identify men with a high risk of prostate 
cancer although their PSA is low. 
 
III 
To investigate the 
follow-up of 
pathological PSA 
values in men living 
in Stockholm between 
2004 and 2012. 
Men who were living in 
Stockholm between 2004 and 
2012 and underwent a core 
biopsy of the prostate. 
Background population in 
Stockholm 
 
 
 
Survival analysis. Population-
based. 
67 and 58% of men aged 50-59 and 60-
69 years, respectively, with a PSA >10 
ng/mL undergo a prostate biopsy within 
one year of the PSA test. One out six 
men diagnosed with an advanced 
prostate cancer had a pathological PSA 
more than 6 months prior to their 
diagnosis 
 
The situation in Stockholm, with an 
unstructured follow-up of pathological 
PSA testing, is suboptimal.  
 
IV 
To investigate if the 
rate of severe 
infectious 
complications has 
increased during the 
last 10 years in 
Stockholm. 
 
To investigate if men 
undergoing a prostate 
biopsy have a higher 
mortality rate. 
 
Prostate biopsies performed in 
Stockholm from 2003 to 2012. 
The men were linked to 
microbiological laboratories. 
 
 
 
 
Logistic regression analysis. 
Standard mortality rate. 
Population-based. 
The proportion of men with symptoms 
suggestive of blood stream infection 
rose from 1.14% in 2003 to 2.31% in 
2012. Mortality rates were not higher in 
men undergoing a prostate biopsy 
compared with Swedish men in general. 
 
 
The infectious complication rate has 
more than doubled in 10 years, which is 
likely attributed to an increase in 
multidrug-resistant bacteria. Patients 
and physicians have to be aware of this 
increase when deciding to perform a 
prostate biopsy. 
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2 BACKGROUND 
 
2.1 EPIDEMIOLOGY 
2.1.1.1 Incidence of prostate cancer in Sweden 
During the last two decades the incidence rate of prostate cancer has increased substantially 
in Sweden. The incidence rate in 1970 was 71 new cases per 100 000 men and rose steadily 
to the mid-1990s when it reached 131. Thereafter, the rate increased faster and reached its 
maximum in 2009 when 229 new cases per 100 000 men were detected (Figure 1). The main 
reason for the incline in incidence is most certainly due to the increased testing by PSA, 
which was introduced in the 1990s. Prostate cancers that have been diagnosed in more recent 
years show a lower stage at detection compared with earlier diagnosed prostate cancers. The 
median age at diagnosis has decreased from 74 years in 1996 to 70 years in 2005 [1]. 
 
Figure 1. 
Incidence and mortality rate for prostate cancer per 100 000 men in Sweden, crude rate. 
Incidence rate from Socialstyrelsen, statistikdatabasen, mortality rate from NORDCAN, 
(Accessed 20140921) [2,3]. 
 
2.1.1.2 Mortality 
Scandinavian countries, together with North America, have among the highest mortality rates 
worldwide. Although the incidence of prostate cancer has increased fourfold in the last two 
decades in Sweden, the mortality rate has been relatively stable throughout the last four 
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decades. Although the disease today is detected earlier and at a lower stage it has not lead to a 
decrease in mortality, until recently. During the last five years the mortality rate has 
decreased slightly (Figure 1). The reduction in mortality witnessed over the last few years is 
probably an effect of the widespread PSA testing that began in the late 1990s [4]. 
Mortality in prostate cancer is very dependent on the grade of the disease. Men diagnosed 
with an aggressive disease will have an affected course of life whereas men with a non-
aggressive disease will most likely succumb to other diseases, even without treatment [5-­‐8]. 
Screening studies done to measure the effects of screening on prostate cancer mortality have 
been performed. Two large randomised studies were presented in 2009: the European study, 
ERSPC and an American trial called PLCO. The ERSPC trial showed a 20% relative risk 
reduction in mortality at nine years of follow-up whereas the American trial could not 
demonstrate any benefits of PSA screening [9,10]. These studies will be more extensively 
discussed in a later chapter. 
 
2.2 RISK FACTORS 
Prostate cancer is a multifactorial disease with no clear aetiology. No specific event is known 
to trigger the disease and no specific causes are known that influence its progression. 
Evidence exists that both genetics and the environment play a role in disease initiation and 
development. There are three established risk factors: age, family history and ethnic origin. 
2.2.1.1 Age 
Prostate cancer is relatively uncommon before the age of 50. The median age of diagnosis is 
68 years with 63% being diagnosed after the age of 65 in the US. The median age for 
diagnosis in Sweden is 70 years of age [1,11]. 
Autopsy studies performed on men dying from other causes than prostate cancer have 
indicated that latent prostate cancer is common, and the prevalence increases with age. In 
men in their 4th decade of life, 8.8-27% harboured small foci of prostate cancer, for men in 
their 5th decade of life the proportion was 14.8-34%. For Asian men, these proportions are 
lower in younger ages but reach the same levels later in life. This is interesting since the 
mortality rates for prostate cancer are much higher for Caucasian than for Asian men [12-­‐14]. 
 
  10 
2.2.1.2 Family history 
For investigative purposes, prostate cancer can be divided into three groups: sporadic, 
familial and hereditary. Familial prostate cancer is defined as cancer in a man with more than 
one affected relative. Hereditary prostate cancer occurs in men with more than three affected 
relatives, i.e. men with three prior generations where prostate cancer has been diagnosed or in 
men with two or more close relatives diagnosed with the disease before the age of 55. 
Sporadic cancers occur in men with a negative family history [15]. 
The relative risk for men with an affected father is 2.17 times higher than for a man with an 
unaffected one, while the risk for a man with a brother diagnosed with the disease is 3.37. 
The relative risk for a man with more than two affected first-degree relatives is 5.08 [16]. 
2.2.1.3 Ethnic origin 
There are great differences in age-standardised incidence rates for prostate cancer in different 
continents and countries. Northern Europe, the United States, Australia and New Zealand for 
example have among the highest age-standardised rates, reaching more than 100 new cases 
per 100 000 men per year. Countries in Asia have significantly lower rates: the rate for Japan, 
for example, is approximately 30 new cases per 100 000 men per year (Figure 2) [17]. 
 
 
Figure 2. 
Incidence of prostate cancer worldwide (Age-standardised rates) [17](copyright, webpage 
accessed 20140918). 
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Afro-American men in the United States have among the highest risk of all men, 
considerably higher than for Caucasian men. 
An intriguing fact is that men who move from Japan to the United States increase their risk, 
and approach the risk of American men [18]. This suggests that not only genetic factors 
influence the risk of developing prostate cancer, but also external exposures such as 
environment and perhaps dietary factors contribute to the risk. 
 
2.1 ANATOMY AND PHYSIOLOGY 
The prostate is located in the male pelvis, circumflexing the urethra. It lies below the urinary 
bladder in front of the rectum. At the bottom of the pelvic floor lies the apex of the prostate, 
the urethra exits the prostate in the apical region and enters the penile structures. The vas 
deferens, which leads the sperms from the testicle to the lumen of the urethra, enters the 
prostate between the rectum and the prostate. The seminal vesicles are located at the base of 
the prostate, close to the bladder and in close abundance to the vas deferens.  
The neurovascular bundle runs at the lateral surface of the prostate. The inferior vesicle 
artery, with its origin from the iliac internal artery, supplies the prostate with blood. The veins 
draining the prostate run in the same bundle and eventually enter the inferior vesicle vein 
which later drains into the inferior internal vein. 
The nerves transmitting signals to accommodate erection also run in the neurovascular 
bundle; which is of clinical importance as these nerves are sensitive and might be traumatised 
during radical treatment of the prostate [19,20]. There is some evidence that nerves in this 
region also partially supply the urinary sphincter and, thus, play a role in urinary continence [21]. 
The prostate is a gland, and its growth is testosterone-dependent. Before puberty, the gland is 
the size of a cherry, but during puberty it grows to the size of a walnut weighing 
approximately 18 grams. For some men this growth continues throughout life, eventually 
causing a problem of micturition.  
The main function of the prostate is to produce Prostate-Specific Antigen, which is an 
enzyme belonging to the serine protease group. Its main purpose is to liquefy the semen at the 
time of ejaculation making the sperms more motile – thereby increasing the chances of 
fertilising the egg. 
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The prostate is subdivided into different anatomical/histological zones with slightly different 
properties. For example, the inner middle region circumflexing the urethra, the transition 
zone, is predominantly responsible for an older man’s difficulties to void as this part grows 
with age. The majority (85%) of the prostate cancers are found in the peripheral zone – where 
the dorsal parts are accessible per rectum for clinical staging (Figure 3) [22]. 
 
Figure 3.  
The prostate gland and its zones and their predisposition to prostate diseases [23](reprinted 
with permission from Nature Publishing Group). 
 
2.2 SYMPTOMS OF PROSTATE CANCER 
In the very early stages of prostate cancer, the patient rarely complains of any symptoms. In 
the later stages some men may complain of problems emptying the bladder – but this is fairly 
uncommon. Most men with voiding problems do not have a clinically significant prostate 
cancer but a benign prostatic hyperplasia causing the symptoms. 
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In the advanced stage of prostate cancer men may complain of skeletal pain as a result of 
metastasises. Some may also present with hydronephrosis and renal damage as a consequence 
of the tumour pressing against the ureters hindering urine to pass normally from the kidney to 
the bladder. Pain in the lower abdomen is rarely related to prostate cancer. 
2.2.1.1 Clinical findings 
The first steps to take when meeting a patient with symptoms or anxiety about having a 
prostate cancer are to analyse the PSA and to palpate the prostate. If laboratory results or the 
DRE raise the suspicion of prostate cancer a histological or cytological evaluation is 
important. This information, together with DRE and PSA, can provide important prognostic 
information and also guide the physician whether or not to evaluate lymph node status by 
means of an MRI or bone metastasis by means of a bone scintigram.  
 
2.3 DIAGNOSTIC MARKERS OF PROSTATE CANCER 
An optimal diagnostic marker can differentiate men with a prostate cancer from those without 
the disease. A marker that at a certain threshold identifies all men with the disease is said to 
have a high sensitivity, whereas a marker with a high specificity correctly classifies those 
without the disease to a high degree. The optimal marker has both a high sensitivity and a 
high specificity. Unfortunately, no such marker has yet been found for prostate cancer. A 
number of markers have been described but only a few have reached everyday clinical 
practice. 
2.3.1.1 Prostate-Specific Antigen 
The discovery of PSA is the work of several researchers independent from each other. In 
1960, Flocks identified species-specific prostate antigens. In 1964 Hara identified a prostate-
specific antigen in the semen, which could be used in forensic medicine when investigating 
rapes. Ablin identified two antigens in the prostate, one was prostatic acid phosphatase and 
the other, which needed further investigation, was called prostate-specific antigen. In 1966 
Hara published an article describing the γ-seminoprotein, which would later be proven to be 
PSA. In 1980, Papsidero succeeded in measuring PSA in serum. Building on the work of this 
early research Chu and colleagues were able to patent the discovery and identification of PSA 
in 1984. But it was not until 1987 when Stamey published an article in the New England 
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Journal of Medicine where he showed that the stage* of prostate cancer was related to the 
PSA level measured in serum. After this, it was concluded that PSA could be used as a 
tumour marker for prostate cancer (Figure 4). Stamey also showed that PSA was not 
measurable after a prostatectomy thereby making it useful as a tool to monitor disease 
progression [24,25].  
Despite its name PSA is not prostate specific, other organs as well, such as normal prostate 
tissue and malignant breast tissue and adrenal and renal carcinomas may produce it, but 
concentrations in serum from these localities are not clinically relevant. PSA can be elevated 
not only due to prostate cancer but also due to other diseases such as benign prostatic 
hyperplasia or urinary tract infection [22].  
 
Figure 4. 
Relation of the concentration of PSA to the clinical stage of prostate cancer in 127 patients 
(reproduced with permission from [25], Copyright Massachusetts Medical Society). 
 
An optimal cut-off to discriminate men who are harbouring the disease from those who do 
not has not been found. It has been shown that the proportion of men diagnosed with a 
prostate cancer with a PSA of 2-3 ng/mL is approximately the same as the proportion of men 
who have a PSA higher than the normally used cut-off of 3 ng/mL [26]. The prostate cancer 
prevention trial showed that the risk of prostate cancer increases as PSA increases [27]. It is 
also clear from this trial that a large proportion men with an elevated PSA up to >6 ng/mL do 
                                                
* In this article the authors used the Whitmore-Jewett staging, which is not commonly used today, where A1 
disease represents the most highly differentiated cancer that has not spread and D when the disease has spread 
to other organs. 
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not harbour a prostate cancer, out of those 150 with a PSA >6 ng/mL 43.3% had a prostate 
cancer. 
Diagnostic or surgical events such as biopsy of the prostate, TUR-P or TUR-B, also 
transiently increase the level of PSA in the blood [28]. The intra-individual change can also 
be up to 15-20% when PSA is analysed on different occasions [29,30]. DRE does not 
influence the level of PSA to such an extent that it plays a clinical role [31]. Normal physical 
activity does not raise the PSA although extreme cycling might raise the level if the blood 
sample is taken within a short time of the exercise, but there are other published papers with 
contradicting results [32-­‐34]. Urinary tract infections cause an increase in PSA and the 
elevated value may be persistent for a very long time.  
2.3.1.2 Free to Total Ratio of PSA 
In the early 1990s it was discovered that not all PSA in serum binds to proteins, some also 
exists in its free form [35,36]. It was shown that the level of the bound vs. the unbound PSA 
differed among men with and without prostate cancer [36,37], and that a low free to total 
ratio was associated with a risk of prostate cancer [38-­‐44]. In 1998, Catalona et al. published 
a paper in which they sought to address this issue and suggested to use a cut-off of 0.25 
where a higher value indicated that, to a higher extent, BPH was responsible for the increase 
in PSA. The f/t PSA has been validated in PSA ranges of 4-10 ng/mL [45]. Swedish 
urologists have mainly used a cut-off of 0.18, which also has been validated for men with a 
PSA of 3 ng/mL or less. Men with PSA in these ranges and a f/t PSA >0.18 can probably be 
screened with longer intervals and do not have to undergo DRE as frequently as other men. 
But for men with a PSA below 3 ng/mL and a f/t PSA <0.18 with a normal prostate as 
defined by DRE, 9 out of 42 (21%) men undergoing a prostate biopsy harboured a prostate 
cancer [46]. As with PSA, no clear-cut line can be drawn for when to consider a value 
pathological or not. The free to total ratio is also affected by urinary tract infections and a low 
value can persist for a long time after the symptoms have passed [47]. 
2.3.1.3 Human Kallikrein 2 
This protease shares approximately 80% amino acid homology with PSA, and it has been 
shown that human kallikrein 2 (hK2) activates pPSA to active PSA [48]. hK2 is measured in 
blood. It is expressed in higher levels in cancerous tissue than PSA and 
immunohistochemically it stains the tissue differently compared with PSA. More intense 
staining is seen in Gleason 4 to 5 compared with PSA [49,50]. hK2 is measured in much 
lower concentrations in the blood compared with PSA [51]. The additive value of using hK2 
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in combination with PSA is not clear, but might play a role to increase the specificity of 
prostate cancer testing in the low ranges of PSA [52]. The test has not yet been implemented 
in clinical routine in Sweden.  
2.3.1.4 Single Nucleotide Polymorphisms – SNPs 
Deoxyribonucleic Acid (DNA) is the chemical structure that holds the genetic information – 
it is organised in chromosomes. The human genome consists of 46 chromosomes where 23 
are inherited from the mother and 23 from the father. A gene is a specific sequence of DNA 
that can be transcribed to a specific order of amino acids that constructs a protein. Each group 
of three nucleotides translates into a specific amino acid and the order of the amino acids is 
important for the function of the protein. Each nucleotide is called a base pair. Alterations in 
the genomic sequence and base pair can lead to alterations in the function of the protein, 
which can lead to either a disease or risk of developing a disease. These alterations are called 
single nucleotide polymorphisms. 
A genome-wide association study is a classical case-control study where men with the trait 
are compared to men without it. Blood is generally the source of the DNA that is analysed. 
Usually a SNP array is used where millions of different SNPs can be analysed at the same 
time. If one variant is more common in men with the disease that variant is said to be 
associated with the disease. By using this method, the whole genome can be explored 
efficiently. In these types of analysis where more than a million SNPs are investigated in 
huge populations there will be false positive associations. By setting a “genome wide 
association significance” level (p) at 5x10-8 the large majority of the false positive results can 
be disregarded. Once a set of significantly associated risk SNPs has been identified they must 
be validated in at least one independent population to be truly confirmed as associated with 
the disease. The common way of reporting the association with a disease is to report the per 
allele odds ratio of the SNP. The median OR for SNPs associated with a disease is 1.3 and, 
very rarely, the OR is greater than 3. The variations in SNPs explain only a small part of one 
patient’s risk of developing a certain disease. 
An argument against these types of studies is that they are not hypothesis driven; they are 
more or less like a fishing expedition, where findings are interpreted afterwards. Many of the 
SNPs associated with a specific disease lie outside of exons in known genes, most likely in 
regulatory regions of the genome – regions whose functions are more or less unknown today. 
Although some of the SNPs associated with prostate cancer lie in known genes. 
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The first SNP shown to be associated with prostate cancer was described in 2006. It was 
located in the 8q24 region, which is intergenic [53]. It is thought that this region regulates the 
Myc expression, which is a known proto-oncogene [54]. It has been estimated that the 
heritability of prostate cancer is 58% [55]. The heritability is explained as what proportion of 
observed differences in a certain trait in a population that is explained by genetic variance. In 
the field of prostate cancer, 100 base pair alterations (SNPs) have been identified and 
confirmed to be associated with a risk of developing prostate cancer. These 100 SNPs are 
estimated to explain 33% of the heritability of prostate cancer. The most recent SNPs were 
published during the autumn of 2014 [56]. Zheng et al showed that men with a higher 
number of risk alleles in combination with family history had a higher risk of prostate cancer [57]. There is no clear evidence that any SNP is associated with the risk of developing an 
aggressive prostate cancer. One advantage of SNPs is that they only have to be analysed once 
– they do not change with age, prostate volume or infection. Since SNP analysis is cheap, 
almost the same cost as analysing a PSA, it is a marker that may be used in screening for 
prostate cancer. 
2.3.1.5 PCA3 
RNA-based tests are the most developed type of markers for prostate cancer in urine. In 1999 
it was shown that prostate cancer cells express far more mRNA from the PCA3 gene than 
normal tissue and benign prostatic hyperplasia tissue. This mRNA does not produce any 
known protein so the level of mRNA has to be measured directly. Prostate cancer cells 
express in median 66 times more PCA mRNA than normal and hyperplastic tissue. After 
DRE the level of PCA3 mRNA can be analysed in the voided urine, however the PCA3 
mRNA levels have to be normalised to the levels of PSA mRNA. Multiplying the ratio of 
PCA3 mRNA to PSA mRNA by 1000 then creates the PCA3 score. A Dutch multicentre 
study demonstrated that the PCA3 test had the same sensitivity but better specificity than 
PSA alone when testing for prostate cancer [58]. A TMA-based platform has been developed 
which is used after prostatic massage in normal voided urine. The test has been proven to 
work in a first biopsy setting where it improves the AUC when combined with PSA, prostate 
volume and DRE findings [59]. Although PCA3 may be used in the primary setting of 
identifying men who have a high risk of prostate cancer it is still too expensive to be used in 
everyday practice. PCA3 may play a role when deciding upon a rebiopsy when the initial 
prostate biopsy was negative for cancer in order to avoid a follow-up prostate biopsy [60]. 
This test is not routinely used in Sweden but there is a commercial test available. 
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Urine would make a useful fluid for prostate cancer screening, however the tests developed 
so far require prostatic massage before evaluation, which makes it unsuitable as a screening 
test today. The high cost of the commercial test lowers its utility as a screening test. 
 
2.4 PATHOLOGICAL EVALUATION OF PROSTATE SPECIMENS 
In order to diagnose a prostate cancer a microscopic evaluation of the tissue has to be made. 
A tissue examination of the prostate can reveal prognostic information. There are different 
methods to acquire the tissue. Either it is collected during surgery for other reasons – for 
example TUR-P, or it is decided that a man undergoing investigation for voiding problems or 
a suspicion of prostate cancer, should undergo a tissue sample. The tissue can be retrieved 
either by a FNA or a set of core biopsies of the prostate. The pathologist interprets the 
characteristics of the prostate cells and/or the gland structure to decide whether or not a 
prostate cancer is present. The architecture of the cells or glands is related to the prognosis of 
the disease. For tissue retrieved by FNA the grading is from 1 to 3, where 3 represents the 
least differentiated type [61]. In core biopsies, the Gleason score is reported. In some 
instances a clinical diagnosis of prostate cancer may be done without the need of specimen 
evaluation – for example when a man has an extremely elevated PSA, a palpable tumour and 
bone metastasis – then a clinical diagnosis can be made. 
2.4.1.1 Gleason Grading System 
A score is created based on the glandular differentiation and growth pattern of the prostate. 
The lowest score, 1, is attributed to glands with high differentiation most resembling the 
normal prostate tissue. Areas with lower differentiation are given a higher score, where 5 is 
the highest possible [62].  
A Gleason score lower than 3 should rarely be used and almost never when grading prostate 
cancer in prostate biopsies. The Gleason sum, constructed by adding the score of the most 
prevalent pattern to the second most prevalent pattern, is reported by the pathologist. In 2005 
an international consensus meeting was held and a modified Gleason grading was presented 
(Figure 5). The most important change was that the most aggressive area should always be 
reported. For example, a prostate tumour with a large area of Gleason 3 and a smaller area of 
Gleason 4 and a minute representation of Gleason 5 should now be reported 3+5=8 instead of 
3+4=7 as it was reported in the initial grading system [63]. 
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The Gleason grade is closely correlated to the prognosis after radical treatment as well as to 
the natural course of the disease [64-­‐66]. 
 
Figure 5. 
On the left, the original Gleason pattern (by D.F. Gleason in 1966). On the right, the updated 
Gleason grading from the ISUP conference in 2005 [63] (Reprinted with permission, 
copyright). 
 
2.5 CORE BIOPSIES OF THE PROSTATE 
For histological evaluation of a specimen a larger chunk of tissue is needed than when doing 
a fine needle aspiration (cytological examination). By using core biopsies this can be 
achieved. This enables the pathologist to decide whether or not prostate cancer is present and 
to assign a Gleason Grade to a cancer. 
During the late 1980s a sextant scheme was used, meaning that six cores were taken from the 
prostate. The needle is directed by using an ultrasound probe inserted to the rectum and 
biopsies are taken from the base, middle and the apical region of the prostate bilaterally. 
Modifications have been done and more cores have been added to the scheme. As of today, 
most urologists use a 10-12-core scheme directing the biopsies laterally as the cancer is more 
common in the peripheral zone of the prostate [67-­‐69]. In repeat biopsies, performed when 
the initial round of biopsies were inconclusive or where there is still a suspicion of prostate 
cancer, some of the cores should be directed to the apical ventral and transitional zone of the 
prostate [70,71]. 
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2.5.1.1 Taking prostate biopsies using image guidance 
Traditionally, an ultrasound device has been used to guide the biopsy needle. The ultrasound 
probe is placed in the rectum together with a needle guide. The ultrasound aids the physician 
to direct the needle in the areas of the prostate that need to be sampled. The ultrasound does 
not aid the clinician to decide whether or not a cancer is present, but it assists in assessing the 
size of the gland and to introduce local anaesthesia before taking the biopsies.  
Over the last few years MRI has won ground and the images produced can be fused into an 
ultrasound device thereby aiding the clinician to guide the biopsy needle to areas where there 
is a high suspicion of prostate cancer – so called fusion targeted biopsies. The MRI can also 
aid the clinician to direct the needle, without fusion technology, to a suspect lesion possibly 
reducing the number of unnecessary penetrations of the rectal mucosa [72]. In a repeat 
biopsy setting, the MRI is good at detecting anterior prostate tumours that are missed in the 
regular primary biopsy scheme [73,74]. A recent publication shows promising results when 
including the MRI in the initial evaluation of a patient with a suspicion of prostate cancer to 
avoid diagnosing men with low-risk tumours and to reduce the number of cores needed to 
find clinically significant prostate tumours [75]. But there is still not enough evidence or 
health economical benefits to include MRI in the standard evaluation of men with a suspicion 
of prostate cancer [76]. 
 
2.6 COMPLICATIONS FOLLOWING A PROSTATE BIOPSY 
Prostate biopsies are usually done as an outpatient procedure. The patient is recommended 
prophylactic antibiotics before the procedure. The probe is inserted in the rectum following a 
palpation of the prostate. Local anaesthesia is administered to minimize the discomfort. The 
needle goes through a channel in the rectal probe and then a guidance line shows where the 
needle will take the tissue sample. The majority of patients tolerate the procedure but find it 
somewhat uncomfortable. Regular anaesthesia is rarely needed. A summary of the most 
common complications is presented in table 1. 
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Table 1. Complications following a prostate core biopsy. A summary of several studies [77-­‐89] 
Symptom	   %	  affected	  men	  after	  biopsy	  
Haematuria 33.8	  -­‐	  64.5	  
Haematospermia	   6.0	  -­‐	  90.1	  
Rectal	  bleeding	   11.5	  -­‐	  40.0	  
Acute	  urinary	  retention	   0.11	  -­‐	  1.7	  
Urinary	  tract	  infection	   0.9	  -­‐	  6.0	  
Bloodstream	  infection	   0	  -­‐	  2.8	  
Hospitalisation	   0	  -­‐	  6.9	  
 
2.6.1.1 Pain 
In early years the transrectal core biopsies were performed without local anaesthesia [90,91]. 
This was to some extent acceptable when only a few cores were taken. As a consequence of 
the development of more extensive biopsy schemes it has been shown that local anaesthesia 
is effective in reducing the pain experienced by the patient [92]. The European Guidelines for 
Prostate Cancer consider local anaesthesia as “state of the art” [76]. 
2.6.1.2 Bleeding 
Rectal bleeding is experienced by almost half of the men undergoing a prostate biopsy. This 
usually fades away within 12-24 hours. Haematuria (blood in the urine) is also common and 
usually diminishes within a few days. Haematospermia (residual blood in the ejaculate) is 
very common – most patients experience it and notice it for up to four weeks although some 
may complain of it for up to a couple of months afterwards. This is not dangerous for the 
patient or his partner. Bleeding complications rarely require hospital treatment [93]. 
2.6.1.3 Infection 
Infectious complications vary from mild urinary tract infections to severe septic shock and, in 
rare cases, death. Up to 6% of men undergoing a prostate biopsy experience mild fever and 
have a positive urine culture after the procedure. A recent Swedish study claimed that 6% of 
patients undergoing a prostate biopsy receive a prescription of a urinary tract infection related 
antibiotic within 30 days of the procedure [84]. Up to 2.8% have a sepsis after the procedure [94]. In comparison to other European countries, Sweden has been relatively spared from the 
problem of multi-resistant bacteria. One of the theories behind this is that Swedish health 
authorities and doctors are cautious in prescribing antibiotics. The antibiotic use per capita in 
Sweden is among the lowest in Europe [95-98]. Over the last few years, however, a 
significant increase in the number of infections caused by these resistant strains of bacteria 
has been noticed internationally, including in Sweden [99,100].  
  22 
2.6.1.4 Clinical routine in Sweden with regards to prophylactic antibiotics 
All men are recommended prophylactic antibiotics before the procedure [101]. The standard 
regimen used in Stockholm, Sweden, is ciprofloxacin 750 mg before the procedure. For men 
allergic to ciprofloxacin or where risk factors are present other regimens are used. To this 
date, rectal swabbing and microbial cultures preceding the prostate biopsy are not routinely 
used in Sweden, unless there is a suspicion of an on-going UTI. If there is an on-going UTI 
the biopsy should be postponed. 
2.6.1.5 Mortality rates after prostate biopsy  
Although a prophylactic antibiotic is used and a careful history is taken with regards to 
bleeding disorders or history of medications prolonging the bleeding time, patients do 
experience serious adverse events [93]. Published studies reporting mortality after a prostate 
biopsy show contradictory results. The ERSPC trial published data from three centres where 
no excess mortality at 120 days following biopsy could be seen. The mortality rate in this 
study was 0.24% for men undergoing a prostate biopsy as well as for men in the control 
group [102]. In the PLCO trial the 120-day mortality rate following a prostate biopsy was 
0.95/1000 compared to 1.8/1000 in the control arm [103]. In a Canadian population, the 120-
day mortality rate was 1.3% whereas in a control population it was 0.3% [104]. The 
difference in the studies is still present, but slightly smaller, when restricting the analysis by 
age from PLCO to match the Canadian study. Another reason might be that the compliance to 
biopsy in the PLCO trial was low and that a “healthy volunteer” bias was introduced, that is 
that the men ending up undergoing a prostate biopsy are those who are most concerned about 
their health and are thus more healthy and not as receptive to complications.  
 
2.7 STAGING OF PROSTATE CANCER 
The most widely used system for the classification of prostate tumours is the TNM system. It 
is based on the growth of the tumour, whether or not it is confined to the prostate, and its 
relation to the capsule and nearby structures (Table 2). The “N” and “M” refers to the 
presence of lymph node and bone metastasis, respectively. To evaluate if lymph nodes are 
affected by prostate cancer, a pelvic MRI is done. Bone metastasis is evaluated by bone 
scintigram where a radioactive isotope is injected in the blood stream. The isotope is enriched 
in areas of high skeletal metabolism such as fractures and bone metastasis. This information 
is used to describe the disease and to guide the clinician in suggesting the right treatment for 
the patient.  
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Table 2. TNM classification of prostate cancer [105]. 
 
 
2.8 RISK STRATIFICATION OF PROSTATE CANCER 
Depending on the PSA level and characteristics of the tumour, men are stratified into 
different risk groups. Depending on the risk group different treatment options are available. 
D’Amico developed the most widely used stratification tool in the 1990s. Stratifying men 
into risk groups depending on Gleason Grade, PSA and palpatory findings can be a helpful 
tool when deciding upon relevant treatment for the individual patient [106]. The Swedish 
national health group for prostate cancer has introduced a new group (very low risk) for men 
with a very low risk of progression (Table 3).  
 
 
 
T" Primary"Tumour"
TX# Primary#tumour#cannot#be#assessed#
T0# No#evidence#of#primary#tumour#
T1# Clinically#inapparent#tumour#neither#palpable#nor#visible#by#imaging#
T1a# Tumour#incidental#histologic#ﬁnding#in#5%#of#less#of#@ssue#resected#
T1b# Tumour#incidental#histologic#ﬁnding#in#more#than#5%#of#@ssue#resected#
T1c# Tumour#iden@ﬁed#by#needle#biopsy#(eg.#because#of#elevated#PSA)#
T2# Tumour#conﬁned#within#the#prostate#
T2a# Tumor#involves#oneHhalf#of#one#lobe#or#less#
T2b# Tumour#involves#more#than#oneHhalf#of#one#lobe#but#not#both#lobes#
T2c# Tumour#involves#both#lobes#
T3# Tumour#extends#through#the#prosta@c#capsule#
T3a# Extracapsular#extension#(uniH#or#bilateral)#
T3b# Tumour#invades#the#seminal#vesicle(s)#
T4# Tumour#is#ﬁxed#or#invades#adjacent#structures#other#than#seminal#
vesicles:#bladder,#levator#muscles#and/or#pelvic#wall#
N" Regional"Lymph"Nodes"
NX# Regional#lymph#nodes#were#not#assessed#
N0# No#regional#lymph#node#metastasis#
N1# Metastasis#in#regional#lymph#nodes#
M" Distant"Metastasis"
M0# No#distant#metastasis#
M1# Distant#metastasis#
M1a# NonHregional#lymph#node(s)#
M1b# Bone(s)#
M1c# Other#site(s)#with#or#without#bone#disease#
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Table 3. Risk group stratification used by the Swedish National Health Group for Prostate 
Cancer, which is based on the D’Amico criteria. 
Very	  low	  risk	   T1c, sum ≤6, 1-4 cores positive for cancer out of a total of 8-12 cores, ≤8 mm 
of total cancer length and a PSA density < 0,15 µg/l/cm3 
	  	   	  	  
Low	  risk	   T1a-T2a, Gleason sum ≤6 and PSA ≤ 10ng/mL 
	  	     
Intermediate	  risk	   T2b and/or Gleason sum 7 and/or PSA 10-19.9 ng/mL 
	  	   	  	  
High	  risk	   T2c-T3 and/or Gleason sum ≥ 8 (or extensive growth of 4+3 in more than 50% 
of the cores taken) and/or PSA≥ 20ng/mL 
 
 
2.8.1.1 Prognosis of prostate cancer based on risk group stratification 
The cumulative proportion of men who died due to prostate cancer where no curative 
treatment was performed at the time of diagnosis was associated with the stage of the tumour 
at the diagnosis in a Swedish study. The 10-year cumulative proportion of men who 
succumbed due to prostate cancer was 4.5, 13, and 29% in the low, intermediate, and high-
risk group, respectively. The 15-year cumulative proportions in the corresponding risk groups 
were 9, 20, and 36% respectively [107]. In an American study, the same pattern was seen in 
a study where no curative treatment was given. Men with a high Gleason score, 8-10, had a 
mortality rate of 121 deaths/1000 person-years whereas men with a Gleason score of 6 had a 
mortality rate of 30 deaths/ 1000 person-years [108].  
 
2.9 SCREENING FOR PROSTATE CANCER 
To screen a population for a certain disease has been, and still is, a controversial subject. 
When screening is introduced, the incidence rate of the disease increases and there is usually 
a stage shift of the disease – that is the disease is discovered at an earlier stage because a 
larger proportion of the diagnosed tumours will be detected earlier. The benefits of an earlier 
diagnosis are that a larger proportion of the diagnosed patients could be offered curative 
treatment and thereby symptoms and possibly the risk of dying due to the disease are 
reduced. The pool of prevalent cases will also increase with an increase in the number of 
controls of the patients that have to be undertaken. One objection against screening is that it 
detects a disease in individuals who will never go on to develop symptoms of the disease. 
They will suffer the consequences of the treatment but not benefit from them. This is 
especially relevant in prostate cancer where there is a long lead-time from detection to 
symptoms of the disease. 
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The most obvious outcome for screening is to reduce mortality for a specific disease. How 
many men have to be screened to avoid one death is described by the number needed to 
screen. In screening studies this is done by calculating the absolute risk difference of death in 
the two arms of the study and then inverting this number. This number will indicate how 
effective the screening is in terms of how many men must be invited and participate in the 
screening in order to prevent/avoid one death due to the specific disease. 
2.9.1.1 European Randomized Screening Trial for Prostate Cancer 
ERSPC is a multicentre trial evaluating PSA as a screening tool for prostate cancer with death 
from the disease as the primary end-point. Seven European countries were involved and 72 
890 men in the core ages 55-69 years were included in the screening group and 89 535 men 
were included in the control group. 82% of the screening group were screened at least once. 
The different countries had slightly different inclusion and follow-up criteria. Most centres 
used a cut-off of 4 ng/mL to recommend a prostate biopsy. The screening group had a 
reduced rate of prostate cancer related death of 20% compared with the control group at a 
median follow up time of nine years. The absolute risk difference of dying from prostate 
cancer was 0.00071, which translates to 1408 men having to be screened in order to avoid 
one death from prostate cancer. A follow-up published three years later showed that the 
absolute risk difference of dying from prostate cancer between those screened and those not 
increased with time. It was estimated that the absolute risk difference was 1.07 deaths per 
1000 person years, corresponding to that 935 men were needed to be screened to avoid one 
death in prostate cancer. A follow up of the Swedish part of the ERSPC, conducted in 
Gothenburg, showed that the number of men needed to be screened to avoid one death in 
prostate cancer had declined to 293 after a median follow up time of 14 years. The number of 
men needed to be diagnosed was at this time point 12. It is, however, important to remember 
that a large proportion of the men who are diagnosed with prostate cancer actually have a 
prostate cancer which most likely will not affect their life expectancy [9,109-111]. 
2.9.1.2 Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial 
From 1993 to the end of 2001, men and women between 55 and 74 years of age were 
recruited to participate in the study at 10 centres in the United States. Primary exclusion 
criteria were: current cancer treatment, history of any of the investigated diseases and, from 
1995 onwards, more than one PSA test in the preceding three years. The male screening 
group (n=38 343) was offered annual PSA testing for six years and DRE annually for four 
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years. Men with pathological findings were recommended to seek diagnostic evaluation from 
their primary physicians. The primary end-point was cause-specific mortality. 
The PLCO trial did not show any positive effect on prostate cancer mortality after 10 years. 
This lead to the recommendation, by the U.S. Preventive Services Task Force, not to 
recommend screening for prostate cancer in the United States [112]. However, concerns 
have been raised regarding the fact that 40 to 52% of the men in the control group had their 
PSA analysed, which might have reduced the differences between the two study-arms thereby 
introducing a false result. A second argument as to why this study did not show any benefits 
of screening was that only 41% of the men with a first positive screen test underwent a 
prostate biopsy within one year and 64% within three years. For men with a negative PSA 
test but a positive DRE only 27% underwent a prostate biopsy within three years [113]. 
2.9.1.3 Opportunistic PSA testing 
No country has so far established a screening programme for prostate cancer. But in some 
countries the frequency of PSA testing is so common it may be called opportunistic 
screening. In Stockholm, Sweden, more than 60% of men older than 60 years of age have had 
their PSA analysed in the last five years, and more than 50% of them have been retested 
within 26 months, irrespective of their initial PSA [114]. The opportunistic screening seems 
to have some effect on prostate cancer mortality, but the results are not as good as the results 
reached in structured trials. It has been shown that in areas where PSA testing is common, 
such as Stockholm, the mortality rate is lower than in areas where testing is not as common. 
The rate ratio for prostate cancer mortality in counties with a high degree of PSA testing 
compared to counties with low degree of testing has been described to be 0.81 [115]. This 
suggests that for PSA testing to have a substantial effect on prostate cancer mortality rates the 
testing and follow-up must be structured.  
 
2.10 TREATMENT OF PROSTATE CANCER 
2.10.1.1 Radical Treatment 
The first question the treating physician has to ask is if the patient will benefit from a radical 
treatment of his condition. For men with a low-risk tumour, the risk of dying of prostate 
cancer is small and these men should rarely be recommended radical treatment – especially if 
they are older than 65 years. Men younger than 65 years of age and men with an intermediate 
risk prostate cancer seem to benefit the most from radical treatment. However, there is a 
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reduction in risk of distant metastasis for men in the older age groups, which could be an 
argument to perform surgery on men older than 65 years of age [108,116].  
The assumption that men older than 65 years of age do not benefit from radical treatment is 
based on studies that included patients in the late 1980s or early 1990s, when the median age 
of death in men was lower than it is today. Urologists have adapted to this and now the 
question that is asked is whether or not the man has more than 10 years life expectancy - 
looking more at biological rather than chronological age. If the life expectancy is estimated to 
be more than 10 years the patient will most likely benefit from radical treatment. Information 
on comorbidities can guide the clinician whether or not to recommend the patient to undergo 
radical treatment. A study based on the NPCR estimated the survival rates for men with 
different stages of prostate cancer stratified on their CCI. Men with a high CCI had worse 
overall survival than men without any comorbidity and a greater risk of dying from other 
causes than prostate cancer [117]. This suggests that the choice of treatment should be based 
on the patient’s medical history. Older men with a life expectancy larger than ten years with a 
high-grade disease are likely to benefit from radical treatment and should be offered radical 
treatment, although they have to be informed that there is a substantial risk of side effects in 
these ages. The numbers needed to treat to avoid one death from prostate cancer have been 
shown to be 8 for surgical intervention at 18 years and 10 for radiation therapy in 
combination with hormonal treatment at 10 years [116,118]. 
The most common negative consequences of radical treatment, for both radiation therapy and 
radical prostatectomy, include the risk of incontinence and impotence[119-­‐122]. For 
radiation there is also a risk of suffering from inflammation of the rectum. The impact of the 
side effects has been one of the reasons why prostate cancer screening has not been 
implemented. 
2.10.1.2 Active Surveillance 
Prostate cancer is a disease with a very broad span of prognosis. A large proportion of the 
diagnosed tumours have a very low level of activity and seem to cause no harm to the men 
whereas some tumours are aggressive and most certainly alter the life span of a diagnosed 
man. Several studies have shown that the numbers needed to treat to save one man from 
death from prostate cancer are relatively high – meaning that a lot of men will undergo the 
procedures and suffer the consequences but not benefit from the treatment [116,123]. One 
large American study has shown that men with a low-risk disease can survive for a long time 
without developing metastasis or dying from the disease [124].  
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Swedish health authorities recommend active surveillance for men with a low-risk disease, 
although the patient’s opinion is to be taken into account when making the decision [101]. 
This treatment alternative has increased during the last years. In Sweden the proportion of 
men with a very low risk prostate cancer, who has been offered active surveillance as their 
primary treatment, has increased from 55% in 2009 to 85% in 2013 [125].  
2.10.1.3 Non-curative Treatment of Prostate Cancer 
Men who are diagnosed with prostate cancer and have a life expectancy shorter than 10 years 
and/or a low grade localised disease may be recommended watchful waiting or deferred 
treatment [76]. This indicates that no treatment is initiated until the patient develops 
symptoms from his disease. This may include voiding problems or pain from skeletal 
metastases. When a tumour has progressed this far it is usually not curable but good palliative 
care, such as hormonal treatment, is efficient in reducing symptoms. Hormonal treatment 
strives to reduce testosterone levels since prostate cancer cells are testosterone-dependent. 
Either a surgical or medical castration is recommended to decrease the testosterone levels in 
the body. If the side effects of castration are unwanted or if the tumour is locally advanced an 
anti-androgen therapy, which inhibits the uptake of testosterone in the cells, may be used. 
 
2.11 EPIDEMIOLOGICAL RESOURCES AND SWEDISH REGISTERS 
COMMONLY USED IN PROSTATE CANCER RESEARCH 
2.11.1.1 The Swedish Personal Identification Number 
This code, which is based on the date and year a person is born plus four additional digits 
including a control digit, is what gives strength to Swedish registers and epidemiological 
research. The PIN is unique for each citizen and was primarily introduced to keep track of the 
population for tax and military purposes. It has been in use since 1947 with only minor 
adjustments. All registers use the PIN as the personal identifier and thereby it is possible to 
link registers to each other [126]. 
2.11.1.2 The National Prostate Cancer Register 
The National Prostate Cancer Register started to collect clinical data on all men diagnosed 
with prostate cancer from 1998. Before, this information was collected on a regional basis 
but, through a joint effort, one register for the whole of Sweden was created. Information on 
TNM classification, PSA at diagnosis, and Gleason Grade is recorded. The register also 
contains information on primary treatment and, during the later years, the results of treatment. 
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The register and information collected has been updated on a few occasions. This register 
covers >98% of all the tumours in the Swedish Cancer register [127].  
2.11.1.3 The Swedish Cancer Register 
Since 1958, the Swedish Cancer Register has collected information on all the cancers 
diagnosed in Sweden. Both the pathology laboratories and the clinicians diagnosing a cancer 
are obliged by law to report diagnosed cancers to the register. The Swedish Cancer register 
contains information on WHO grade and TNM classification and how the tumour was 
diagnosed. Validation studies have been performed and the register covers more than 98% of 
all tumours diagnosed [2,128].  
2.11.1.4 The National Patient Register 
The national patient register started registering all hospitalisations for all people receiving 
health care in Sweden. The inpatient part started collecting data in 1964 and contains 
information on main and secondary diagnoses and surgical procedures done (based on ICD-
10), if any, during the hospital stay and at which hospital the health care was given. The date 
of admission as well as the date of leave is registered. The outpatient part of the register does 
not contain information from primary care physicians [129]. 
2.11.1.5 The Swedish Cause of Death Register 
The register used today was established in 1961. It uses the ICD codes and is updated 
annually. At every death a doctor has to report the primary cause and any underlying diseases 
that may have contributed to it for Swedish residents. Based on international standards an 
illness is set as primary cause of death alongside contributing diagnoses. The register is 
complete for up to 99% of all people registered in Sweden regardless if the death occurred in 
the country or elsewhere in the world [130]. 
2.11.1.6 Total Population Register 
Sweden has had a long history of keeping track of its inhabitants. This was done by the local 
churches, which reported to the state for tax and military purposes. The Swedish Tax agency 
took over the responsibility in 1991 and provides information on each citizen´s PIN, sex, 
birth, address, marital status, and country of birth, emigration and immigration as well as date 
of death. This resource is useful for population-based research when person-time has to be 
taken into account.  
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2.12 STHLM COHORTS 
2.12.1.1 STHLM-0 
STHLM-0 is a register-based cohort consisting of men who have done at least one PSA test 
in Stockholm County since 2003. Data have been retrieved from the three laboratories, 
Karolinska Universitetslaboratoriet (KUL), Aleris Medilab (AM), Unilabs (UL), doing all 
PSA analysis in Stockholm, including information on total and free PSA where available as 
well as date of analysis.  
The men were linked to the pathology registers where information on date of incoming 
prostate samples and result of the pathology report were retrieved. These data are updated 2-3 
times per year. The data has been linked to the National Prostate Cancer Register, Swedish 
Cancer Register, National Patient Register, Swedish Prescription Register, Swedish Cause of 
Death Register, Educational Register and Total Population Register. The men who have 
undergone a prostate biopsy have also been linked to the Swedish Intensive Care register and 
to the microbiological databases at the departments performing all blood cultures in 
Stockholm. As of 1st of January 2014 this database contain information on 410 000 men with 
at least one PSA test in the Stockholm area. 
There is missing data with regards to free PSA which is because the results of the analysis 
performed by the laboratory were dictated to the analysis demanded by the physician 
ordering the blood sample and only ordered analyses have been saved. There is also 
incomplete data regarding PSA analysis for the southern part of Stockholm from 2003 to the 
beginning of 2006 due to loss of data from the laboratory. This represents only 15% of the 
PSAs analysed during this time period. 
2.12.1.2 STHLM-1 
Men who between 01/012005 and 31/12/2007 underwent a prostate biopsy were invited to 
donate blood for SNP analysis. Exclusion criteria were: age above 80 years, other cancer than 
prostate cancer diagnosed at the prostate biopsy, prior prostate cancer diagnosis, deceased at 
the time of invitation or a non-valid Swedish personal identification number. 7035 men were 
invited and 5241 accepted participation, donated blood, and filled-out a questionnaire 
covering family history of prostate cancer. The men were linked to the PSA registers and 
NPCR. 2135 of them had a first prostate biopsy positive for cancer regardless of PSA level. 
3791 men had a PSA <10 ng/mL, out of which 1359 were diagnosed with a prostate cancer.  
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2.12.1.3 STHLM-2 
During 2010 and 2011 men who for any reason were recommended to analyse their PSA 
were invited to participate in the STHLM-2 cohort at the time of the blood sample procedure. 
PSA was analysed by ordinary methods, extra blood and urine samples were collected and 
the men were asked to fill out a web-based questionnaire. A total of 27 350 men were 
included and linked to the above-mentioned registers by using the STHLM-0 cohort. The 
cohort consists of men without prostate cancer, men with an already known prostate cancer, 
and men who, within a relatively short time after the PSA test, were diagnosed with prostate 
cancer. This cohort has been used for validation studies of the biomarker panel used in the 
STHLM-3 trial. 
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3 AIMS OF THE THESIS 
The overall aim of this thesis was to investigate prostate biopsy patterns and trends and to 
explore and improve prostate cancer diagnostics as well as describing the increasing 
problems with multi-resistant bacteria and its implications for the diagnosis of prostate cancer 
 
In particular, the thesis aimed:  
 
• To evaluate if the single nucleotide polymorphisms associated with prostate cancer 
can be used to reduce the number of unnecessary prostate biopsies for men with a 
PSA of <10 ng/mL 
• To evaluate if the single nucleotide polymorphisms associated with prostate cancer 
can be used to identify men with a higher risk of prostate cancer in men with PSA 1-3 
ng/mL 
• To describe prostate biopsy patterns and time from PSA test to prostate biopsy in men 
living in Stockholm, Sweden 
• To evaluate if serious infectious complications after prostate biopsies are increasing in 
Stockholm, Sweden 
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4 MATERIALS AND METHODS 
 
4.1 STUDY POPULATIONS 
4.1.1.1 Study I 
A total of 8088 men who had undergone at least one prostate biopsy were identified by 
retrieving data from two out of three pathological departments in Stockholm between 1 
January 2005 and 31 December 2007. These two departments analyse approximately 75% of 
all prostate biopsies done in the region. Exclusion criteria were: age above 80 years, no valid 
PIN, deceased at the time of invitation, a prostate cancer diagnosis prior to 1 January 2005 
and other cancer than prostate cancer diagnosed at the prostate biopsy. In total, 7035 men 
were invited and 5241 accepted and donated blood samples. These men were linked to 
laboratory databases to match PSA values to their prostate biopsies. For cancer status and 
clinical information regarding the tumours the men were linked to the NPCR and the SCR. 
The analysis was further restricted to men with a PSA lower than 10 ng/mL – the reasoning 
behind this selection is that in this PSA range only 25% of men will have a positive biopsy 
and hence a greater specificity would save a large proportion of the unnecessary biopsies. 
SNP selection was based on all published PC-associated SNPs until October 2009. The SNPs 
used had to be validated in at least one independent study population. Genotyping was done 
using MALDI-TOF mass spectrometry based on allele-specific primer extension with iPLEX 
chemistry (Sequnom Inc., San Diego, CA, USA). Hardy-Weinberg calculations were 
performed. A total of 36 SNPs were genotyped in the entire sample, rs2660753 failed 
completely, and the others had an average success rate of 98.6%. 
The genetic risk score was created by summing the number of risk alleles at each of the 35 
successful SNPs multiplied by the logarithm of that SNP’s OR. Aggressive cancer was 
defined as T3-T4, N1, M1 or Gleason 4+3 or higher. 
4.1.1.2 Study II 
From the STHLM-2 cohort, men with a PSA between 1 and 3 ng/mL and between 50 and 69 
years of age at the time of inclusion were identified. 2696 men with no prior history of 
prostate cancer or prostate biopsies were identified and genotyped. For the genotyping, we 
selected all known SNPs reported to be associated with prostate cancer and replicated in at 
least one independent study population and published before October 2012. In total, 50 
relevant SNPs were chosen. The ORs and risk allele frequency were calculated by using a 
nested case control population from the STHLM-2 cohort. We used the same genotyping 
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method as in Study I and the average success rate was 98.7%, rs13385191 failed completely. 
The score was created in the same way as in Study I. Based on the genetic risk score a man 
was categorised as belonging to the low, intermediate or high-risk group. 
A randomised stratified selection (based on their genetic score) of men was invited to 
participate. Based on the power calculation it was estimated that 200 men needed to undergo 
a prostate biopsy. From earlier studies we knew that the response rate would be high and 
therefore a total of 860 men were invited. There were 200 time slots available for prostate 
biopsies and 192 men signed up for a prostate biopsy, 14 were not medically fit or were using 
anticoagulative medication, 6 men did not show up at the scheduled appointment. Two 
urologists, who were blinded to the genetic risk score, performed the biopsies in the 172 men. 
The prostate biopsies were taken using a pre-set scheme with 10 laterally directed cores if the 
gland was smaller than 35cc and 12 cores if it was larger. An ultrasound-guided technique 
was used, and all patients received prophylactic antibiotics and local anaesthesia. One 
pathologist, who was also blinded to the genetic risk score, evaluated all specimens. 
4.1.1.3 Study III 
From STHLM-0 we identified all prostate samples between 1 January 2003 and 31 December 
2012 (no. of specimens =56 014). The men and the dates of their prostate biopsies (data from 
KUL, AM and UL) were linked to the NPR to exclude specimens taken during other surgical 
interventions such as TUR-P and TUR-P (no. of specimens excluded=11 536). The men were 
also linked to the TPR in order to adjust for emigration outside the Stockholm area (no. of 
specimens excluded = 2193). When restricting to the years studied, 2004-2012, there were 38 
880 prostate biopsies performed during this time period. In a subgroup analysis we selected 
men who at the time of biopsy were diagnosed with an advanced prostate cancer defined as 
≥T3, N1, M1 or PSA ≥20 ng/mL at diagnosis. In total, 4 236 men met this definition and 
1497 were aged 50-69 years and had no prostate biopsy recorded prior to their diagnostic 
prostate biopsy. 
4.1.1.4 Study IV 
From STHLM-0 we identified all men who had undergone at least one prostate biopsy from 1 
January 2003 to 31 December 2012. These men were linked to NPR, NPCR, CR, SIR, and 
SCOD. The reasons for not linking these men to the TPR were: 1) as the outcome studied, 
having a positive blood culture, in most cases occurred within a week and a minute 
proportion of the men migrated in this time interval. 2) Data on hospital admission from the 
NPR and the SCOD is nation-based, which means that a man undergoing a prostate biopsy in 
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Stockholm and is admitted to a hospital or who died shortly after the biopsy elsewhere in the 
country will be registered. Data was retrieved from the clinical microbiological laboratories 
performing blood cultures (KUL and UL) and data concerning results and biograms were 
retrieved for those who were positive. In the cohort used for analysis we had access to 56 076 
prostate specimens. When excluding histological specimens other than core biopsies of the 
prostate and restricting to age > 30 at time of biopsy there were 44 047 biopsies left 
performed in 32 196 men from 2003 to 2012. 
 
4.2 STATISTICAL METHODS 
All p-values were based on two-sided hypothesis and p<0.05 was considered statistically 
significant. All statistical analyses were performed using SAS 9.2, R or STATA 11.2 for 
Mac. 
4.2.1.1 Statistical Models 
4.2.1.1.1 Logistic regression 
Logistic regression is used in epidemiological research when the relationship between a 
dichotomous variable and one or more independent variables is analysed. By adding the 
independent variables one at a time the effect of the variable and the effect of confounding 
can be appreciated. In a univariate analysis, only one independent variable is used to predict 
the outcome, whereas in multivariate analysis several independent variables may be added. 
Logistic regression can also be used to predict the probability of an event occurring. The odds 
are defined as the probability of an event divided by 1 minus the probability, and the odds 
ratio (OR) is calculated by dividing the odds for one group divided by the odds for another 
group and it is used to compare the probabilities of a certain event occurring for two different 
groups. In these studies the estimated OR is reported with 95% confidence intervals. Used in 
Studies I, II, III, IV. 
4.2.1.1.2 The Kaplan-Meier estimator 
The Kaplan Meier function can, for example, be used to estimate the proportion of men 
surviving a specific disease at a certain time after an exposure and can thus be used to 
compare the outcome of different treatments. The model is flexible and can be used to 
estimate any event dependent on time and allows for stratification on different groups. An 
event does not have to be a single event but can be a grouping of several events, as in study 
III. The function takes every individual’s attributed time into account and is thereby useful 
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when study subjects are lost to follow-up, die, or do not want to be part of the investigation 
any longer; the study subject is in other words censored. The proportion of survivors is 
calculated at certain time points where the censoring is taken into account – thereby adjusting 
the calculated proportions to the maximum of retained study subjects and in the next set of 
calculations the number of men at risk is the total number of men left in the life table.  
In our studies we frequently plotted the result as 1- survival rather than the survival to 
illustrate the cumulative effect of the event. Used in Study III. 
4.2.1.1.3 Net reclassification index 
This test is used to measure the improvement of a prediction model when adding a variable. It 
was presented by Pencina in 2008 and is used when new biomarkers are tested [131]. It was 
developed to complement the AUC (the area under the receiver operating characteristics 
curve; a plot of sensitivity vs. 1-specificity over a wide range of cut-offs for a specific 
biomarker), as this may be cumbersome to interpret and because very strong associations 
between a new marker and the outcome of a model only lead to tiny changes in the AUC. The 
improvement or reclassification compares the subjects being correctly classified to the ones 
being wrongly classified in the two groups experiencing the event or not. A positive NRI 
indicates that the new biomarker increases the model’s predictive performance. Used in 
Studies I, II. 
4.2.1.1.4 Standard Mortality Ratio 
The standard mortality ratio is used when a comparison wants to be made between the study 
subjects and the overall population. By dividing the observed deaths in the cohort with the 
expected number of deaths calculated by the age-standardised mortality rate a ratio is given. 
If the ratio is larger than 1 the studied group has an increased mortality compared with the 
other group. Care has to be taken when choosing the comparison group with regards to age 
and exposure of risk factors. The results may differ quite substantially and, thereby, the 
interpretation of the results.  Used in Study IV. 
4.2.1.2 Test of significance and trends 
4.2.1.2.1 Cochran - Armitage test for trend 
This test is used to test the presence of an association between one variable with two 
categories and a variable with several categories. It is a variant of the Pearson chi-squared 
test, which is used to establish whether or not an observed frequency of an event differs from 
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the expected frequency. It is most useful to confirm when there is a suspected trend in the 
data. It is commonly used in genetic association studies. Used in Studies I, II, IV. 
4.2.1.2.2 Cuzick’s test for trend 
Cuzick’s test is a development of the Wilcoxon rank-sum test in which a variable is tested for 
three or more ordered groups. It is a non-parametric test, which makes it robust against 
distribution assumptions. Used in Study II. 
4.2.1.2.3 Wald’s test 
Wald’s test is a parametric test used in logistic regression analysis to test the significance of 
separate coefficients. It is equal to the coefficient in the logistic regression divided by the 
standard error. The square of the test statistic is asymptotically chi-square distributed with 
one degree of freedom, a property that is applied to compute p-values. If the sample size is 
large Wald’s test gives similar results as the likelihood ratio test. Used in Study IV. 
4.2.1.2.4 Likelihood ratio test 
The likelihood ratio test is used to test the goodness of fit between two models. A model with 
more variables is compared with a simpler model to see if it fits the observed data better. A 
more complex model will always be at least as good as the simpler model and, in most cases, 
it will be better and have a higher likelihood score. To obtain the test statistic, the difference 
in the logarithm of the likelihood score for the more complex model and the basic model is 
computed and then multiplied by two. This test statistic is asymptotically chi-squared 
distributed with degrees of freedom equal to the difference in number of parameters in the 
more complex model and the basic model. If the test is significant the more complex model is 
said to fit the data better compared with the basic model and, therefore, the added variables 
are of importance. Used in Study I, II, IV. 
4.3 STATISTICAL ANALYSIS 
4.3.1.1 Study I 
The association between each SNP and prostate cancer at biopsy was tested using the 
Cochrane-Armitage test for trend. The OR with 95% CI for each SNP was calculated by 
using logistic regression. Age, family history, PSA and f/t PSA were the known risk factors 
and their association with prostate cancer at biopsy was explored using logistic regression. 
When using the same dataset to both fit the prediction model and explore the model’s 
predictive capacity, there is always a risk of overestimating the predictive performance of the 
included variables. Cross-validation can be used to mitigate this effect. In cross-validation, 
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the dataset is partitioned into training and prediction sets, where the model is fitted to the 
training set and then used to predict the outcome in the prediction set. This is repeated for as 
many times as the original dataset has been tiled. Each time a new part of the original data set 
is used for the prediction. At the end, the average result of the coefficients in the prediction 
model is reported. In this study we performed a 10-fold cross validation.  
Three models were created and compared: 1) non-genetic model combining age, PSA, f/t 
PSA and family history; 2) same as 1 and adding the genetic risk score; 3) a hypothetical 
genetic prediction model. These three models were compared using a likelihood ratio test. 
Specificity was tested using the net reclassification index. The predictive performance was 
estimated by calculating the AUC for each model. All reported p-values were based on two-
sided hypothesis.  
The hypothetical genetic prediction model (optimal genetic) was created under the 
assumption that the sibling relative risk of developing a prostate cancer is 2.5 and that the 
model is polygenic. By retracting the calculations in Pharaoh et al. the predictive performance 
of such model can be estimated [132]. 
4.3.1.2 Study II 
A logistic regression model based on PSA, f/t PSA, age, family history, DRE and prostate 
volume was created and compared with a logistic regression model with the same variables 
with the addition of the genetic score. The different models were compared using model fit 
by likelihood ratio testing. The predictive performances of the regression models were 
compared using the net reclassification index. Cuzick´s test for trend was used to compare the 
different risk strata and the findings of cancer in each of them. 
4.3.1.3 Study III 
4.3.1.3.1 Classifying prostate core biopsies 
Biopsies prior to a cancer diagnosis were classified as either the first recorded diagnostic 
biopsy or a subsequent diagnostic biopsy. We further classified diagnostic biopsies as being 
either positive for cancer or not. The reference date of a biopsy associated with a prostate 
cancer was defined as either: (i) the date of cancer diagnosis for men with a prostate cancer 
diagnosis based on TUR-P, clinical diagnosis or cytology; (ii) the date of biopsy referral for 
biopsies within 30 days of a cancer diagnosis or, otherwise; (iii) the date of cancer diagnosis. 
All biopsies performed more than 30 days after the reference date were assumed to be active 
surveillance biopsies. For all analyses, we included biopsies performed during 2003, giving at 
least 12 months of biopsy history. 
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4.3.1.3.2 Statistical modelling 
To estimate the proportion of men who had a biopsy or other clinical investigation as a 
function of time from a first PSA test, we considered an event as the earliest biopsy, a repeat 
PSA test that was lower than 4 ng/mL, or a cancer diagnosis. We censored men at emigration, 
end of study follow-up (31 December 2012) or death. We did not censor for a subsequent 
PSA test, as this is potentially informative for having a subsequent biopsy. The variance 
estimates for the Kaplan-Meier estimators were not adjusted for repeated events within the 
same individual and confidence intervals should be interpreted cautiously. As a sensitivity 
analysis, we calculated the Charlson Comorbidity Index (CCI) based on hospitalisations in 
the year preceding the PSA test and stratified time to subsequent biopsy or clinical 
investigation by a CCI of 0.1 or 2+. The CCI was calculated for ICD-10 using SAS code 
from the Manitoba Centre for Health Policy. 
4.3.1.3.3 Subgroup analysis 
We defined men with advanced prostate cancer as having a T3, T4, N1 M1 stage tumour or a 
PSA of ≥20 ng/mL at the time of diagnosis. We reported results for men aged 50-69 years, 
since such men were more likely to be candidates for radical treatment if they would have 
been diagnosed at a lower stage.  
We investigated the proportion of men with advanced prostate cancer that had an earlier PSA 
test. For the time t prior to a cancer diagnosis we used the Kaplan-Meier estimator to 
calculate the cumulative proportion (=1-survival) of a PSA >4 ng/mL between time t and 
eight years prior to diagnosis, taking account of emigration. 
4.3.1.4 Study IV 
Frequencies and proportion biopsies that were followed by a blood culture within 30 days 
were calculated, as well as the proportion of positive cultures and bacteria findings. 
Crude- and adjusted logistic regression models were used to estimate odds ratios (OR) with 
95% confidence intervals (CIs) as measures of relative risk of having a blood culture drawn, 
which was used as a proxy for symptoms of a bloodstream infection. The variable of main 
interest was calendar year of biopsy. To assess possible linear trends, all variables in the 
adjusted model were also included, one at a time, as continuous variables and linearity were 
tested using the Wald test. All models were adjusted for the correlation between biopsies 
using the sandwich estimator of variance for clustered data (where biopsies from the same 
man were considered a cluster). 
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To evaluate whether men undergoing a prostate biopsy experience a higher mortality, we 
compared the 30- and 90-day mortality rate in the study population with the general 
population, by calculating age-standardised mortality ratios (SMRs) with 95% CIs. 
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5 RESULTS 
 
5.1.1.1 Study I 
A total of 5 239 men were successfully genotyped. There were 2 542 men with a PSA lower 
than 10 ng/mL and complete data on the other risk variables. We only calculated the risk of 
prostate cancer for the first recorded biopsy. In the multivariate analysis all risk factors were 
associated with the outcome, which was defined as cancer or no cancer at the biopsy (Table 
4).  
 
Table 4. Result of multivariate logistic regression of the risk factors for men with a PSA <10 
ng/mL (n=2542). 
Variable OR (95% CI) Cumulative AUC (95% CI) 
PSA 1.17  (1.12-1.22) 0.55  (0.53-0.57) 
F/T PSA 0.69  (0.66-0.73) 0.60  (0.58-0.62) 
Age 1.17  (1.12-1.22) 0.63  (0.60-0.65) 
Family History 1.41  (1.29-1.54) 0.64  (0.62-0.66) 
Genetic Score 1.52  (1.45-1.59) 0.67  (0.65-0.70) 
 
The logistic regression analyses were used in a prediction model where the outcome gave a 
risk of being diagnosed with prostate cancer. This was done for the non-genetic, the genetic 
and a hypothetical genetic model. A distinct cut-off that perfectly separates men with disease 
from those without cannot be found. Therefore we chose to visualize how many biopsies 
could be saved at different cut-offs and to what cost in terms of missed aggressive cancers 
(Table 5).  
 
Table 5. Number of biopsies performed, cancers detected, and biopsies saved at different risk 
cut-offs for the non-genetic, the genetic, and the optimal genetic model. 
Model,	  %	   Performed	   No.	  of	  saved	  biopsies	  (%)	  
Cancer	  
Detected	  
Cancer	  
missed	  	  
No.	  (%)	  
Aggressive	  
cancer	  
detected	  
Aggressive	  
cancers	  missed	  	  
No.	  (%)	  
Non-­‐
genetic	   1000	   0(0)	   365	   0(0)	   60	   0(0)	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	  
20	   949	   51(5.1)	   352	   13(3.6)	   59	   1(1.7)	  
25	   871	   129(12.9)	   338	   27(7.4)	   56	   4(6.7)	  
Genetic	  
	   	   	   	   	  
	  	  
20	   878	   122(12.2)	   344	   21(5.8)	   58	   2(3.3)	  
25	   773	   227(22.7)	   321	   44(12.0)	   55	   5(8.3)	  
Optimal	  
Genetic	  	  
	   	   	   	   	  
	  	  
20	   745	   255(25.5)	   348	   17(4.7)	   59	   1(1.7)	  
25	   686	   314(31.4)	   340	   25(6.8)	   57	   3(5)	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The number of saved biopsies is dependent on the risk one is willing to take to miss cancers. 
If the threshold for a biopsy lies at 20% the genetic model would save 122 biopsies, at a 
threshold of 25% 227 biopsies would be saved. The number of aggressive tumours missed 
when not performing a prostate biopsy on all 1000 men would be 2 and 5, respectively. 
5.1.1.2 Study II 
A total of 860 men were invited after successfully genotyping 2696 individuals with a PSA 
between 1 and 3 ng/mL and 192 men were booked for prostate biopsy out of which 172 men 
underwent the procedure. There were 50, 79 and 43 men in the low-, intermediate- and high-
risk group respectively based on their genetic score. In men with low risk, 18% (n=9) were 
diagnosed with prostate cancer, 28% (n=22) were diagnosed in the intermediate risk group, 
and 37% (n=16) diagnosed in the high-risk group. We also explored if the SNPs had a 
discriminatory possibility for intermediate or high-risk prostate cancer, defined as Gleason 7 
or higher. In the low-, intermediate- and high-risk group there were 2%, 5% and 12% 
respectively, but the trend analysis was borderline statistically significant. The result of the 
multivariate logistic regression is shown in table 6. 
 
Table 6. Results from the multivariate logistic regression analysis. Family history is defined 
as any first-degree relative with prostate cancer. 
Risk	  factor	   OR	   95%	  CI	  
Genetic	  score	   1.6	   1.05-­‐2.45	  
Total	  PSA,	  ng/mL	   1.06	   0.72-­‐1.54	  
f/t	  PSA	   0.98	   0.95-­‐1.02	  
Age,	  yr	   1.08	   0.99-­‐1.18	  
Prostate	  volume,	  cm3	   0.95	   0.91-­‐0.99	  
Family	  history,	  yes/no	   0.73	   0.29-­‐1.81	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Figure 7. 
The estimated risk and observed outcome of positive prostate biopsies in 172 men without a 
known previous prostate biopsy and a PSA of 1-3 ng/mL, by their decile of genetic risk. 
(Reprinted with permission, copyright European Urology) 
 
The proportion of positive findings on biopsy correlate with the genetic risk score as seen in 
Figure 7. The oversampling at the end-deciles is visualised by the grey shaded columns in the 
figure.  
 
5.1.1.3 Study III 
In 2012 there were 133 118 PSA tests performed in a population of 483 807 men older than 
40 years of age in Stockholm, Sweden. The number of prostate biopsies was 4694. We 
noticed a clear increment in the number of prostate biopsies done after a cancer diagnosis, 
from 233 in 2004 to 582 in 2012, which were interpreted as active surveillance biopsies. 
Total number of biopsies per year and type was also calculated; the number of primary 
diagnostic biopsies is presented in table 7. 
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Table 7. Number of primary diagnostic biopsies performed in Stockholm, Sweden, by year.  
	  	   Year	  of	  Prostate	  Biopsy	  
	  	   2004	   2005	   2006	   2007	   2008	   2009	   2010	   2011	   2012	  
Primary	  biopsies	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
Without	  cancer	   2046	   2023	   1747	   1621	   1433	   1543	   1499	   1577	   1833	  
With	  cancer	   1450	   1446	   1225	   1151	   1201	   1407	   1366	   1378	   1407	  
Total	  nr.	  	   3496	   3469	   2972	   2772	   2634	   2950	   2865	   2955	   3240	  
 
 
 
Table 8. Estimated proportion of men who underwent a prostate biopsy within one and two 
years after a PSA test in Stockholm, Sweden, 2004-2012. 
	  	   	  	   PSA	  4-­‐10	  ng/mL	  
	  	  
	  
at	  1	  year	   at	  2	  years	  
Age	  
group,	  yrs	   at	  risk	  (no.	  of	  men)	   Proportion	  (%)	   CI	  95%	   Proportion	   CI	  95%	  
50-­‐59	   7853	   58	   57-­‐59	   67	   66-­‐67	  
60-­‐69	   20177	   45	   44-­‐45	   55	   54-­‐55	  
70-­‐79	   15844	   27	   26-­‐27	   35	   34-­‐36	  
	  	  
	   	   	   	  
	  	  
	  	  
	  
PSA	  >10	  ng/mL	  
	  	  
	  
at	  1	  year	   at	  2	  years	  
Age	  
group,yrs	   at	  risk	  (no.	  of	  men)	   Proportion	  (%)	   CI	  95%	   Proportion	   CI	  95%	  
50-­‐59	   1793	   67	   65-­‐69	   73	   71-­‐74	  
60-­‐69	   5770	   58	   57-­‐59	   65	   64-­‐65	  
70-­‐79	   6336	   38	   37-­‐39	   45	   44-­‐46	  
 
To estimate the time from PSA test to a clinical investigation defined as prostate biopsy we 
performed a survival analysis where an event was defined as either a man being diagnosed 
with prostate cancer, having undergone a prostate biopsy or had a repeat PSA lower than 4 
ng/mL. Men were censored if they migrated away from Stockholm, died, or at the end of 
study period. We found that for men in ages 50-59 and 60-69 years with a PSA of >10 ng/mL 
67%, and 58 %, respectively, had performed a prostate biopsy within one year. The 
corresponding proportions for men with a PSA of 4-10 ng/mL were 58% and 45%, 
respectively (Table 8). 
As PSA testing is frequent among men living in Stockholm [114], we investigated what 
proportion of individuals, who were diagnosed with an advanced disease, defined as either 
T3/T4, N1, M1 or a PSA >20ng/mL, had a pathological PSA registered prior to their cancer 
diagnosis at certain time intervals for men aged 50-69 years (n=1497). One out of eight of 
these men had a first recorded PSA above 4 ng/mL more than six months prior to their 
diagnosis. To visualise the distribution of their first recorded PSA value, we plotted this as a 
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function of time before diagnosis (Figure 8). Three out of four men diagnosed with an 
advanced disease did not have a PSA taken prior to their diagnostic PSA test. 
 
Figure 8. 
Plot over first known PSA for men aged 50-69 years at time of diagnosis of an advanced 
prostate cancer (n=1497).  
 
 
Figure 9. 
Plot of median PSA at first known prostate biopsy in Stockholm, 2004-2012, stratified by age 
category at time of biopsy. 
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In Figure 9, the median PSA value at the first recorded biopsy is presented stratified by age 
category at the time of the prostate biopsy and year of biopsy. The median PSA is clearly 
related to the age of the man undergoing a prostate biopsy. Younger men perform a biopsy at 
a lower PSA than older men. There is a tendency that the median PSA at the first recorded 
biopsy is dropping at the end of the study time for all age groups. 
 
 
Figure 10.  
The cumulative proportion of men who, prior to 31-12-2012, underwent a prostate biopsy, 
stratified by age at 31-12-2012. This figure includes all types of transrectal ultrasound-guided 
prostate biopsies (e.g. primary diagnostic, follow-up and active surveillance biopsies). 
 
The proportion of men living in Stockholm who, during the last nine years, underwent at least 
one prostate biopsy is shown in figure 10. At five years prior to 31-12-2012, 2.3% of men 
aged 50-59 years had undergone a prostate biopsy, for men aged 60-69, 70-79 and >80 years 
the proportion is 7.5%, 8.5% and 5%, respectively. As the time prior to 31 December 2012 
increases, the proportion of men who has undergone a prostate biopsy increases almost 
linearly for all ages.  
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5.1.1.4 Study IV 
There were 44 047 prostate biopsies performed in men older than 30 years of age between 
2003 and 2012. On 620 occasions men underwent a blood culture within 30 days of the 
prostate biopsy, out of which 266 were positive. The proportion of men undergoing a blood 
culture in 2003 was 1.14% whereas the proportion was 2.32% in 2012 and the corresponding 
proportions for positive cultures were 0.38% in 2003 and 1.14% in 2012. This increase in 
infectious complications is also reflected by the proportion of men admitted to hospital and 
discharged with an ICD-10 code related to infection which increased from 1.26% in 2003 to 
1.85% in 2012, as seen in figure 11.  
 
Figure 11. 
Number of prostate biopsies and proportion of men undergoing blood cultures, having a 
positive culture and proportion of men being hospitalised within 30 days of the prostate 
biopsy performed in Stockholm, Sweden, 2003 to 2012.  
 
The vast majority of blood cultures (75%) were performed within one week of the prostate 
biopsy (Figure 12). During the study period, the median time for hospitalisation fluctuated 
around three days although some men were hospitalised for months following a prostate 
biopsy (Figure 13). 
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Figure 12. 
Time from prostate biopsy to blood culture in days in men who underwent a prostate biopsy 
in Stockholm, Sweden, 2003 to 2012. 
 
 
 
Figure 13. 
Boxplot over time of hospitalisation following a prostate biopsy for men hospitalised within 
30 days of a prostate biopsy with an ICD code related to an infection, Stockholm, Sweden, 
2003 to 2012. 
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The most common pathogens found in the cultures were E. coli (84.1%), Klebsiella spp (4%) 
and other enterobacteriacea (4%). There was a clear increase in the proportion of culture with 
biograms reporting resistant bacteria over the years (p<0.05).  
 
 
Figure 14. 
Number of positive cultures during the study time and the reported proportion of bacteria 
resistant to specific antibiotics. 
 
In 20% of all blood cultures and in more than 50% of the positive cultures a bacteria resistant 
to ciprofloxacin or trimethoprim/sulfamethoxazole was found (Figure 14). Ciprofloxacin is 
commonly used as a prophylactic antibiotic in the prostate biopsy setting. 
The level of PSA had no correlation to the risk of undergoing a blood culture or having a 
positive blood culture. A higher age at the time of biopsy seemed to reduce the risk of 
undergoing a blood culture after a prostate biopsy. The risk was lower, however, for men who 
had undergone multiple previous biopsies. The later a biopsy was performed during the study 
time the higher was the risk of undergoing a blood culture as well as having a positive culture 
(Table 9). As seen in Table 9, there is no evident difference if the outcome is having a blood 
culture compared with having a positive blood culture. The CCI is strongly associated with 
the risk of having a positive blood culture. 
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Table 9. Adjusted logistic regression analysis reporting OR for men undergoing a blood 
culture and for those with a positive culture compared with those who did not undergo a 
blood culture or had a negative culture. 
	  	   	  	  
Having	  a	  blood	  culture	   Having	  a	  positive	  blood	  culture	  
Risk	  factor	  
	  
OR	   95%	  CI	   OR	   95%	  CI	  
PSA,	  ng/mL	  
	  
1.00006	   0.9998-­‐1.0003	   0.9998	   0.9989-­‐1.00006	  
Age,	  year	  
	  
0.99	   0.98-­‐1.002	   0.97	   0.96-­‐0.99	  
CCI	  
	  
1.78	   1.61-­‐1.96	   1.67	   1.45-­‐1.93	  
Previous	  biopsies	   0.86	   0.75-­‐0.97	   0.74	   0.60-­‐0.91	  
Year	  of	  biopsy	   1.11	   1.07-­‐1.15	   1.18	   1.12-­‐1.24	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6 DISCUSSION OF FINDINGS 
 
6.1.1.1 Study I 
By adding 35 SNPs to a risk prediction model based on age, PSA, f/t PSA and family history 
it was estimated that the proportion of biopsies performed can be reduced by between 12.2 to 
22.7%.  
As with other diagnostic tests, the genetic model is not perfect. The cost of saving biopsies is 
paid in missed cancers. By setting the cut-off at 20% the genetic model would miss 5.8% of 
the cancers and, with a cut-off at 25%, 12% would be missed. For non-aggressive cancers this 
does not necessarily lead to any severe consequences, at least not in the short run, perhaps not 
even in the long run, since Gleason 3+3 tumours do not seem to have the possibility to 
metastasise [124].  
Under the assumption of a polygenic model and that the sibling relative risk of developing a 
prostate cancer is 2.5, an optimal genetic prediction model was constructed. This model 
estimates the predictive value if all genetic information with regards to association of prostate 
cancer risk in the genome was known. The optimal genetic prediction model would save 
between 25.5 and 31.4% of biopsies. 
However, the number of aggressive prostate cancers missed would increase from 3.3 to 8.3% 
of the missed cancers at the first biopsy session. Strategies have to be found to take care of 
those men with a negative first biopsy but with a persistent high risk of aggressive prostate 
cancer. The Swedish guidelines suggest that these men shall undergo a repeat prostate biopsy 
within three months [101]. By using MRI or a saturation biopsy model, the detection rate 
after a first negative biopsy session can be increased [74,133]. It has also been described that 
genetic prediction model based on SNPs may be of value when deciding if a man should 
undergo a repeat biopsy or not [134]. 
Translated to a fictive situation in Stockholm, Sweden, the genetic model would save 
approximately 250 to 480 biopsies per year at the cost of missing 5 to 11 aggressive cancers 
at the primary biopsy (based on an average nr. of primary diagnostic biopsies of 3000 per 
year out of which 2100 are performed in men with PSA <10; combination of Table 7 and 
Study IV). 
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6.1.1.2 Study II 
Previous studies have shown that men with a low PSA have a significant risk of prostate 
cancer and also that the proportion of individuals diagnosed with a clinically relevant prostate 
cancer is not negligible [26,135]. In this study, we showed that a genetic risk score could be 
used to identify men with low PSA, 1-3 ng/mL, at a higher risk of prostate cancer in. There 
was a tendency that the men with the highest genetic score were, to a higher degree, 
diagnosed with a clinically relevant prostate cancer, defined as Gleason 3+4 or higher, that at 
least would render a discussion of radical treatment. In fact, eleven out of the 47 men 
underwent radical treatment based on the findings on their first biopsy. 
Neither PSA nor f/t PSA could discriminate healthy from ill men in this very selected cohort. 
Prostate volume seemed to be correlated to the risk of being diagnosed with prostate cancer, 
where a smaller volume increased the risk. 
The value of diagnosing men at an earlier time point is not obvious. There is no doubt that 
screening does reduce mortality, but some studies have shown that screening for prostate 
cancer detects the tumour earlier in patients undergoing screening than in the control groups. 
This lead time varies between 5 and 13 years [136,137]. For men with a disease that 
demands radical treatment this is most likely positive, but for a large proportion, whose 
tumours are low grade, this means that they are labelled with a prostate cancer diagnosis and 
suffer the psychological effects of that. Some of these men will likely undergo treatment with 
the risk of suffering from the side effects.  
For a screening programme to be efficient the test used has to be easily accessible and 
reasonably priced and the disease has to have a preclinical phase where it is possible to detect 
it before it has reached an incurable stage. Blood borne markers, such as PSA in combination 
with SNPs fit these criteria and would most likely work in a screening programme for 
prostate cancer. An analysis of all SNPs associated with risk of prostate cancer costs 
approximately 10 euros if done in a routine setting. A PSA analysis costs approximately 8 
euros.  
Other tests such as DRE and/or ultrasound or MRI of the prostate are, today, either too 
unspecific or too expensive but might be considered later. 
6.1.1.3 Study III 
Rates of PSA testing and retesting have been described and the situation in Stockholm, 
Sweden, is noteworthy: 60% of all men above the age of 60 years have, during the last five 
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years, had at least one PSA test. This despite the fact that there is no official screening 
programme. And a large proportion of these individuals were retested within 26 months 
regardless of their initial PSA [114]. What this testing lead to in regards of transrectal 
ultrasound-guided prostate biopsies was, however, not clear.  
Our study, which counts biopsies performed in men living in Stockholm, shows that an 
average of 4300 transrectal ultrasound-guided biopsies are done annually in Stockholm, 
Sweden, in a population of approximately 483 000 men aged 40-79 years.  
The transrectal ultrasound-guided biopsy is a frequently performed procedure. During a 5-
year period every 13th man aged 60 to 69 years has undergone the procedure and in a 9-year 
period more than 1/10 in the same age group has done it. When subtracting biopsies resulting 
in a prostate cancer diagnosis, the proportion is approximately halved – which in the golden 
setting with a perfect prediction tool could be avoided. 
The proportion of men with elevated PSA levels that did not perform a prostate biopsy within 
one year of the PSA test was unexpectedly high, especially in individuals aged 50-59 years 
with a PSA >10 ng/mL; one third of these men did not perform a prostate biopsy within one 
year of their PSA test, which corresponds to 590 men. The causes for this, however, are 
unknown. The PSA test may have been taken at a time when the patient was suffering from a 
urinary tract infection and a repeat PSA was analysed which was lower, but not lower than 4 
ng/mL as this would have triggered an event in this estimation. Another explanation might be 
that either a doctor or patient delay was responsible. These results are coherent with an 
American study where 2/3 of the patients with an elevated PSA had been evaluated after two 
years of the PSA test. In that study, 18.8% of the men being re-evaluated had a normal PSA, 
and 32.8% underwent a biopsy [138].  
A longer time between PSA and biopsy is correlated with finding more T2c cancers than T2a 
and T2b in men with a shorter time between PSA and biopsy [138]. In another American 
study, the time between a PSA test, and response by clinicians to the test, was studied. In 
15.8% of the cases, the latency between the test results and the action taken upon them was 
more than 180 days [139]. In an optimal setting the time between a test and the response to 
the patient is very short in order to limit the patient’s concerns after undergoing a cancer test. 
We observed that 196 of the men being diagnosed with an advanced prostate cancer (n=1497) 
had a first recorded PSA of >4 ng/mL more than six months prior to diagnosis. A total of 107 
men had a first PSA >10 ng/mL more than six months prior to diagnosis. How their tumours 
would have looked if actions had been taken on their first elevated value can only be 
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speculated about. An Irish study, however, showed that a delay of more than 12 months was 
significantly correlated to a higher PSA at diagnosis, larger proportion of palpable tumours, 
and a higher proportion of leading Gleason 4 in the biopsies than for men with a shorter time 
between PSA and biopsy [140]. Although a lot of men analyse their PSA, approximately 
76% of those aged 50 to 69 years have not had a PSA test prior to their diagnosis of advanced 
disease. At least 16% of men age 60 to 69 and 12% of men age 50 to 59 years would have 
been examined two years earlier if a standardised follow-up, like the Gothenburg part of the 
ERSPC, had been used. It is likely that the tumours of these men would have had a different 
stage at that time. 
The mortality rate for prostate cancer in Sweden has declined minimally over the last few 
years. But it is not comparable to the reduction seen in screening studies. It has been shown 
that in areas in Sweden where PSA testing is more common the mortality rate is lower 
compared with areas where the testing is very prevalent [115]. The situation in Stockholm is 
comparable to the findings in the PLCO trial where only 75% of men with a baseline of PSA 
>10 ng/mL underwent a prostate biopsy within a year. This has been argued to be one of the 
reasons that this trial did not show a reduction in mortality since a large proportion of men 
with high PSAs did not undergo a biopsy and thereby delayed their diagnosis and treatment. 
It is thus easy to draw a parallel to the Swedish situation and the minute reduction in prostate 
cancer mortality although the frequency of PSA testing is high. 
The conclusions from this study is that a transrectal prostate biopsy is a common procedure, 
and that there is room for improvement in several areas. First, the time from a PSA test to a 
performed biopsy is long, second, a large proportion of men with elevated values do not 
undergo the diagnostic procedure at all.. One solution to these problems may be structured 
testing and follow-up.  
A drawback of our study is the retrospective design and the lack of knowledge concerning the 
true reasons why men with an elevated PSA did not undergo a prostate biopsy. 
6.1.1.4 Study IV 
During the ten years of the study, 44 047 prostate biopsies were performed and 620 were 
followed by a blood culture within 30 days of the biopsy. The majority of men underwent the 
blood culture within seven days; 266 of the cultures were positive. 
There is a clear effect of time as expressed by the OR for year of prostate biopsy. This effect 
was prominent, and in 2012 more than 1 out of 50 men who performed a prostate biopsy 
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received symptoms suggestive of bloodstream infection compared with 1 out of 100 in 2003. 
These results are in line with the findings of Lundström et al. who described an increased rate 
of urinary tract infections and hospitalisations after a prostate biopsy over the years [84]. 
Their study, however, only covered men with a known prostate cancer and they used 
prescribed antibiotics as a proxy for urinary tract infection. In our univariate analysis, men 
with a prostate cancer seemed to have an increased risk (OR 1.22) of undergoing a blood 
culture within 30 days compared with men with no known prostate cancer, an effect which 
was not seen in the adjusted model most likely due the effect of the comorbidities.  
Not only did the proportion of men undergoing a blood culture increase but also the 
proportion with a positive blood culture, which tripled during the study period. This is most 
likely attributed to a change in virulence of the bacteria interpreted as a loss of sensitivity to 
the prophylactic antibiotic given at the time of the prostate biopsy.  
From the resistance patterns of the positive blood cultures we could see that the proportion of 
cultures with ciprofloxacin-resistant bacteria has increased substantially over the last few 
years. The same is seen for trimethoprim/sulfamethoxazole. Both of these antibiotics are 
commonly used as a prophylaxis before ultrasound-guided biopsies of the prostate.  
The rate of hospitalisations almost doubled during the time frame studied. This is interesting, 
as the number of beds at hospitals in Sweden for surgical care has dropped from 18 000 in 
1986 to 7000 in 2013. Sweden has one of the lowest numbers of hospital beds per capita in 
Europe. This means that if the numbers of infections continue to increase this will have a 
push-out effect on patients treated for other conditions or planned for other procedures [141,142]. The median time for hospitalisation, ≈3 days, after a biopsy-related infection did 
not change significantly during the study time. 
From an international perspective Sweden has been relatively spared from antibiotic 
resistance in microbes [95]. This is perhaps due to the historically low use of antibiotics in 
Sweden [143]. The belief that a frequent use of antibiotics leads to an increase of multi-
resistant bacteria has led to an information campaign for Swedish doctors and the prescription 
rate for outpatient use of fluoroquinolones has decreased by 17-27% over the last 6 years 
[144].  
The reason for the increase in resistant strains in Sweden is likely multifactorial. One reason 
is probably increasing travel to foreign countries. Up to 24% of healthy volunteers that 
travelled outside Northern Europe were colonized with ESBL-producing Enterobacteriaceae 
upon arrival in Sweden [145]. It is unclear for how long these individuals carry the bacteria. 
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As a comparison it has been shown that up to 46% of patients infected with an ESBL-
producing Enterobacteriaceae carry the resistant strain for up to one year after infection [146]. This indicates that recent travel has to be considered when choosing the proper 
prophylactic antibiotics, especially if the patient is suffering the clinical symptoms of an 
infection.  
The results in this study regarding the situation in Stockholm probably reflect a best-case 
scenario where the prescription rate of antibiotics in the community is low and decreasing 
and the prophylactic regimens before biopsies are reasonably stringent and sparse. From an 
international perspective these rates are fairly low, but for an urologist practising in Sweden 
the development of multi-resistant bacteria is a fearsome prospect.  
 
7 METHODOLOGICAL DISCUSSIONS 
In classical epidemiological research, where causes and diseases in populations are studied, 
several different types of studies can be conducted. In this thesis we conducted cohort studies. 
A cohort study is a longitudinal study, which follows study subjects free from the disease at 
the start of the study and observe who develops the disease within the study period. They are 
thus defined by their exposure and followed up for the outcome. The common denominator 
for those included may be year of birth, place of birth, city they live in and so on. The study 
subjects may also be chosen by a certain common exposure, such as PSA testing or 
transrectal ultrasound guided prostate biopsies in our studies. 
 Cohort studies have the advantage of making it possible to calculate incidence rates and 
absolute risks for a certain outcome. A cohort study may also investigate more than one 
outcome. 
No study is without limitations or errors. The following sections will cover some of these 
aspects and put the studies in this thesis into this context [147]. 
7.1.1.1 Non -systematic vs. systematic errors 
Non-systematic errors 
Non-systematic errors refer to random errors, which occur in all types of studies. They may 
occur during all stages of a study and include errors such as transforming an answer in a 
questionnaire to a dataset and an answer is wrongly typed in as “1” where it should have been 
“0”. Usually the errors are of minor importance and in most studies they also occur randomly 
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occurring in both the cases and controls. These types of errors cannot be corrected for in the 
statistical analysis. A large sample size usually reduces the influence of random errors.  
Systematic errors 
Systematic errors refer to a situation where the error affects the analysis in a non-random 
way. There are mainly three types of systematic errors of interest, information bias, selection 
bias and confounding. Subgroups to these exist and are exemplified below with relevance to 
the studies in this thesis.  
7.1.1.1.1 Information bias 
Misclassification 
Misclassification refers to the situation when the collected information is incorrect. This type 
of information bias can be subdivided into differential and non-differential misclassification. 
The former describes the situation where information on a certain exposure is classified 
differently among those with the disease and those without the disease. The association found 
could either be directed towards the null or away from the null. In non-differential 
misclassification, this error is not associated with the outcome and is thus usually of less 
importance since it mainly dilutes the estimates toward a null result, possibly leading to a 
false negative finding. By using large validated registers these types of error were reduced.  
Recall bias 
When studying subjects retrospectively and collecting information regarding exposure to risk 
factors the subjects who developed the disease of interest may remember exposures 
differently than those who did not developed it. As an example of this in our studies we 
collected exposure status with regards to family history of prostate cancer. Those men who 
developed prostate cancer may have had more time and interest to discuss these topics with 
family members and recollect information regarding the disease status and, thereby, report 
that in a higher degree than those who were not diagnosed.  
This may be the case for Studies I and II where information regarding family history was 
used in the prediction model. It is very difficult to estimate how large this effect is in this type 
of study. 
 
 
  58 
Selection bias 
Selection bias in retrospective cohort studies may be introduced when subjects in one of the 
exposure groups are more or less likely to be selected if they had the outcome that is studied. 
One form of selection bias might be present in Study IV where the mortality rate in men 
undergoing a prostate biopsy is lower than that for the general population for men younger 
than 70 years of age. The selection of men undergoing a prostate biopsy is made by the 
doctors performing the procedure, if a man with severe comorbidities show up for a doctors 
appointment to discuss whether or not to investigate an elevated PSA the doctor might be 
inclined to recommend the patient not to undergo the procedure as other illnesses could be of 
larger concern – thereby selecting only men healthy enough to undergo the biopsy and since 
they are healthier than the average their mortality rate following a prostate biopsy is lower. 
This means that the control population for such calculations has to be chosen carefully not to 
miss any substantial negative effects of the procedure. In the case of study IV the control 
population chosen was the age-matched reported mortality rates for all males in Sweden. We 
considered choosing to calculate the mortality rate for men undergoing a PSA test in 
Stockholm to compare with our cohort, but we argued that PSA testing is so common in 
Stockholm that this would not have made any difference. 
Men lost to follow up could also raise concerns regarding a cohort study. Bias, as an effect of 
this, may occur if there is a difference in loss to follow up in those exposed and those not 
exposed. If men at random, regardless of their exposure status, are lost to follow up this does 
not introduce bias.  
7.1.1.1.2 Confounding 
A confounding effect is when there is a second exposure that is both associated with the 
primary exposure of interest and the outcome, but the secondary exposure is not a direct link 
between the primary exposure and the outcome. Confounding may cause both an over- and 
underestimation of the effect of the primary exposure. There are ways of controlling for 
confounding. The best way in a prospective cohort study is to randomize study subjects to the 
different study arms. This leads to the confounding factors, both known and unknown, being 
likely to be evenly distributed amongst the different study arms. This is however not possible 
to do in the retrospective setting. In these studies, the confounding effect may be reduced or 
controlled by stratification of the study subjects, for example by age and/or sex. The risk for 
the outcome is then analysed in different strata. However there is no guarantee that other 
confounders than the one stratified for are controlled for. The residual confounding could be 
due to incomplete information regarding the confounding variables or unknown confounders 
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that were not controlled for. Another reason might be that the stratification is to coarse or 
even wrong. 
Another way to control for this is to do regression analysis where simpler, unadjusted, models 
are compared to more complex, adjusted, models. How confounders or different exposures 
interact can be estimated by introducing the different variables step by step into the regression 
analysis and seeing how the results differ. It is important to recognise that even after good 
adjustments of the model there will be residual confounding. 
The logistic regression analysis done in Studies I, II, and IV use these methods. Age is an 
example of confounding in study IV, where a higher age is associated with the risk of having 
a positive blood culture in the unadjusted model, but when adjusting the model with Charlson 
Comorbidity Index the age effect vanishes for older men. This was interpreted as if older men 
have a risk of having more severe diseases, which predisposes to a severe infection. and, 
thereby, it is not the age itself which is a risk factor but the comorbidities the older man has 
that is the true risk factor for attaining a severe complication to a prostate biopsy.  
7.1.1.2 Validity 
Validity refers to the question if the study measures what it is intended to study or not. It is 
usually split into two different parts, internal and external validity. The internal validity 
covers the question if the researcher can answer the research question with the presented 
factors available and if the right study design has been used. A study with a high internal 
validity has few or no systematic errors or they have been controlled for. External validity or 
generalizability refers to how well the results of the trial can be used in other populations or 
settings. The external validity is dependent on the internal validity. In Studies I, III and IV we 
used data on historical PSA values where there were missing values between 2003 to 2006 
from a specific region in Stockholm. These tests represented 15% of the tests performed in 
Stockholm during these years. Sensitivity analysis was performed to objectify what impact 
these missing values had on the analysis. By restricting the analysis to other years this effect 
could be estimated. The restriction did not alter the results significantly. This suggests that the 
internal validity with regards to PSA is high and the results are likely to be generalisable.  
7.1.1.3 Statistical hypothesis testing 
Associations between risk factors and outcome may be a result of chance. To demonstrate 
that a finding is not merely a result of chance a statistical hypothesis testing is performed. To 
do this a null-hypothesis is compared with an alternative hypothesis. The null hypothesis is 
usually formulated as if there is no difference between two compared groups whereas the 
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alternative hypothesis claims that there are differences. The next step is to set a limit, p (a 
probability threshold), if the test is lower than this the null-hypothesis may be rejected. This 
limit is usually set at 1 or 5%. The statistical tests are then performed to decide whether or not 
the null-hypothesis can be rejected or not. If the null-hypothesis can be rejected the 
alternative hypothesis is then possible to accept –but it does not automatically state that the 
null-hypothesis is wrong – just that it is not probable under the pre-set requisites.  
Two types of errors can be encountered in hypothesis testing. If the null-hypothesis is true 
and rejected a type 1 error (false positive) is committed. A type 2 error is committed if the 
alternative hypothesis is true and rejected (false negative).  
7.1.1.4 Power calculations 
In order to estimate how large a study has to be in order to detect statistical significant 
differences between studied groups a power calculation is performed. Statistical power is 
inversely related to the probability of making a type 2 error. If the statistical power is high the 
risk of doing a type 2 error is small. As the study is not done yet some assumptions have to be 
made. Firstly, an estimation of how large the difference, or effect size, may be is done. The 
larger the difference the smaller study is needed. The information regarding the effect size is 
often not known before the study but results from similar studies can be used to estimate this. 
The next decision that has to be made is how large the chance should be that one is willing to 
accept for the study to result in a conclusion that is incorrect. This limit is almost always 
chosen at 0.05, which is the probability threshold of making a type 1 error, also called the α-
criterion. The next step is to estimate how large the probability should be to detect a true 
difference; this probability is commonly set to 0.80. After these steps are taken a power 
calculator can be used to estimate the sample size needed. Depending on the study planned 
different formulas is used to estimate either the power or the study size needed. 
When study subjects are invited to participate there will always be some who do not want to 
or cannot participate which means that a slightly larger number of people than are really 
necessary according to the power calculation need to be invited. 
In this thesis we used power calculations to estimate how many men needed to be invited in 
Study II in order to find a statistical significant difference in the groups. Since prostate 
biopsies carry a certain risk for complications it was of great importance to reduce the 
number of men undergoing the procedure. By oversampling at the end-deciles, that is men 
with the lowest and highest genetic risks, we were able to reduce the number of men invited 
and, thereby, limit the number of prostate biopsies performed.  
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8 CONCLUSIONS 
 
• Genetic markers can be used to avoid unnecessary prostate biopsies in men with 
moderately elevated PSA levels 
• Genetic markers can be used to identify men at higher risk of prostate cancer although 
their PSA level is low 
• More than one third of the men with a PSA >10 ng/mL do not undergo a prostate 
biopsy within one year of the PSA test 
• The proportion of men suffering from severe infectious complications after prostate 
biopsies has increased during the last 10 years 
 
The diagnostic pathway for prostate cancer in Stockholm is suboptimal. A large proportion of 
men with a high suspicion of prostate cancer do not undergo a diagnostic procedure within a 
reasonable period of time.  
By using an SNP-based genetic risk score as a complement to the common markers used 
today men at higher risk who do not undergo prostate biopsies today, since their PSA is low, 
would have a chance of being treated earlier. By complementing the PSA test with genetic 
markers, a substantial proportion of biopsies could be spared The use of genetic markers as a 
complement to PSA would also reduce the number of men suffering from severe side effects 
of the prostate biopsy since they would not have to undergo the diagnostic procedure. 
Implementing a structured protocol for prostate cancer testing based on genetic markers and 
PSA would likely improve the current situation. 
  
  62 
9 FUTURE PERSPECTIVES 
 
Prostate cancer is of great relevance to both society and to the people affected by the disease. 
The disease is not only the most common solid malignancy among men in Sweden today but 
also one of the most costly to treat. There are three areas regarding prostate cancer where 
efforts are made and have to be intensified: pre-diagnostic, diagnostic and treatment.  
The pre-diagnostic area includes screening for prostate cancer. When will screening be 
introduced in Sweden? The question is not if but rather when. There is evidence to suggest 
that screening does lower the mortality rate of prostate cancer, but how a screening 
programme should be implemented is not clear. In the ERSPC, different countries used 
different screening intervals but only used PSA as a trigger for biopsy. With the introduction 
of new markers it would be possible to individualise the screening interval in order to 
optimise testing. Men with a low risk of prostate cancer may be screened with longer 
intervals.  Men with a higher risk, but not reaching the cut-off for a diagnostic test, can be 
screened with shorter intervals. This screening protocol would be complex but would be of 
benefit not only for the people paying for the screening but also for the men undergoing it. 
Not only will new markers be used in the screening situation but also in the setting of repeat 
biopsies in men with an increased risk of prostate cancer. New diagnostic and prognostic 
markers will enhance the selection of men who need to undergo repeat biopsies. During the 
fall of 2013 the STHLM-3 study was initiated, in which the primary goal is to reduce the 
number of unnecessary prostate biopsies with retained sensitivity for Gleason 7 tumours. By 
combining the predictive information in SNPs and a number of biochemical markers, such as 
PSA and hK2, the hypothesis is that this can be achieved. In so far more than 60 000 men 
have been invited and 4 000 have undergone a prostate biopsy. The last letter of invitation 
was sent in November 2014 and the preliminary results of the study will likely be presented 
during 2015. 
Regarding the diagnostic area, the prognostic information based on the histological 
architecture of the tumour is fairly good but the process is slow and to some extent 
inaccurate. There is also a problem with interobserver variability. Then there is an uncertainty 
as to whether or not the most aggressive tumour is sampled or not when analysing prostate 
biopsies. To address the problem of correct sampling, better approaches to identify the most 
aggressive tumour in the prostate have to be evaluated. In an effort to do this our research 
group is planning a MRI fusion-guided biopsy study during 2015. A paired design study 
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approach will be used where men with a high risk of prostate cancer are identified through 
the STHLM-3 biomarker panel and invited to undergo a MRI of the prostate. All men will 
undergo a regular 12 core prostate biopsy and those men with a suspect lesion at the MRI will 
undergo directed biopsy as well. Hopefully this will show that MRI can be a part of the 
diagnostic procedure in a screening programme. There is some data suggesting that MRI 
improves the detection of high-grade prostate cancer, meaning that men with no evident 
tumour on MRI do not need to undergo prostate biopsies.  
To address the interobserver variability and the relatively slow process of the histological 
examination, the great advances in genomic research will likely be useful. In a short period of 
time it will be possible to do genomic profiling of prostate tumours as a part of the 
histological evaluation of the specimens, and not only to look for specific mutation but the 
whole tumour genome. The information on the individual mutations will most likely give a 
good answer to the prognosis of the individual prostate cancer in an individual. There is some 
evidence that genomic profiling can be translated to a Gleason Score and thereby contain the 
same prognostic information. If this holds true it means that the diagnosis and prognosis for 
the prostate cancer can be obtained within a couple of days of the biopsy at a reasonable cost. 
By using standardised laboratory analysis equipment the problem of interobserver variability 
could be minimised. This technique is being evaluated for breast and colon cancer and within 
a year the process for prostate cancer will be ready. 
One of the largest problems within the field of medicine for mankind lies ahead of us. The 
increasing problem with multi-resistant bacteria will cause severe harm to people in the 
future. In the worst case scenario the future will be like the past when there were no 
antibiotics. On a global scale the use of antibiotics must be decreased. This can only be done 
through information and education. Although prostate biopsy is a common procedure this is 
not the main driver behind the increasing antibiotic resistance. The urological community can 
contribute by reducing the number of men who need to perform prostate biopsies. An 
individualised prophylactic regime will most likely be used. Before the biopsy a stool sample 
will be sent in and analysed with regards to pathogens in the rectum and their resistance 
pattern. By using this information each patient will receive an individualised antibiotic 
prophylaxis at the time of the prostate biopsy. Another approach is to reduce the number of 
cores taken and to disinfect the needle between each core. During 2015 a large study will be 
undertaken in our group where the biopsy needle will be rinsed in formaldehyde between 
each core. A small study has been done in Canada showing that infection rate could be 
reduced to one third of its current level with this simple routine. 
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Over a longer perspective, liquid biopsies will be performed in blood or urine or a 
combination of these. By analysing circulating fragments of DNA or tumour cells in the 
blood or urine a diagnosis can be set. This can also be used to identify men who after surgical 
treatment might be candidates for adjuvant radiation therapy due to positive surgical margins.  
Prostate cancer treatment has been conservative. In breast, bladder and colon cancer 
treatment the patients are offered multimodal treatments with better results. This must be the 
case for prostate cancer as well. Randomised trials with either docetaxel or abiraterone in 
combination with surgery will be of great interest, with our without the adjuvant radiotherapy 
for advanced cases. Perhaps genetic profiling of the tumour will be of benefit here to identify 
those tumours that are sensitive to a specific treatment. 
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10 POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
Prostatacancer är den vanligaste tumörformen bland män i Sverige. Varje år diagnostiseras 
1800 män i Stockholm och ca 1100 genomgår botande behandling. Antalet män med 
nyupptäckt prostatacancer låg från mitten av 1950-talet till början av 1990-talet relativt 
stabilt, liksom antalet som dog till följd av sjukdomen. I mitten av 1990-talet kom 
cancermarkören PSA som snabbt etablerades som ett test för att bedöma risken för huruvida 
en man hade prostatacancer eller inte. Detta ledde till att antalet män som diagnostiserades 
med prostatacancer ökade kraftigt, däremot låg dödligheten kvar på i princip samma nivå. 
Under senare år har dödligheten i prostatacancer minskat minimalt. 
Det finns tre etablerade riskfaktorer för prostatacancer. Dessa är ålder, familjehistoria och 
etnicitet.  
Det har diskuterats om screening för prostatacancer ska införas i Sverige. Två stora 
internationella studier, ERSPC och PLCO, har visat olika resultat avseende screening. I 
ERSPC minskade dödligheten i prostatacancer med 20 %, medan den amerikanska 
undersökningen inte kunde påvisa några fördelar med screening. En av baksidorna med 
screening är att många av de män som diagnostiseras med prostatacancer har en tumör som i 
de allra flesta fall inte leder till att mannens liv förkortas, även i frånvaro av behandling. För 
att undvika att en man dör i prostatacancer måste 293 män bjudas in till screening. För att 
rädda en man från att dö i prostatacancer måste 8-10 män genomgå behandling.  
Prostatacancer diagnostiseras oftast till följd av att en man har låtit undersöka sitt PSA-värde. 
Är detta måttligt förhöjt, 3-10 ng/mL, har en man en risk på ca 25 % att diagnostiseras med 
prostatacancer. Är värdet kraftigt förhöjt, mer än 50 ng/mL har nästan alla män en 
prostatacancer. Det finns dock inte något strikt normalvärde för PSA; även män med värden 
mellan 1 och 3 ng/mL, som idag anses ligga inom normalvärdet, har risk för prostatacancer.  
PSA testning är vanligt i Stockholm, mer än hälften av alla män äldre än 60 år har gjort 
provet under den senaste femårsperioden. Sex av tio män har upprepat provtagningen inom 
två år oberoende av det ursprungliga värdet. Däremot är det relativt okänt hur många av dessa 
provtagningar som leder till att män genomgår vävnadsprovtagning och också hur lång tid en 
man får vänta från det att PSA värdet är taget till dess att en vävnadsprovtagning är 
genomförd. 
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Under senare år har en rad nya markörer för prostatacancer utvecklats. Bland dessa märks 
Hk2 (Humant Kallikrein 2), vilket är en proteinmarkör, samt genetiska basparsvariationer, 
s.k. SNPs (Single Nucleotide Polymorphisms). De senare är genetiska markörer vilka kan 
mätas i blodet. Dock har ingen av dem har ännu nått klinisk användning i Sverige. 
Män med förhöjd risk för prostatacancer rekommenderas ofta vidare utredning. Hos de flesta 
män innebär detta att en urolog bedömer prostata genom att känna på den samt att 
vävnadsprover av prostata tas via ändtarmen. Dessa prover innebär vissa risker för infektion 
och blödning. Under senare år har risken att behöva sjukhusvård på grund av infektioner ökat 
efter vävnadsprovtagning av prostata.  
Avhandlingens syfte var att undersöka om genetiska markörer kan användas som ett 
komplement till PSA för att öka träffsäkerheten vid utredning av män med ökad risk för 
prostatacancer. Målet var också att undersöka huruvida dessa genetiska markörer kan 
användas för att identifiera män med låga PSA-värden som idag oftast inte rekommenderas 
vidare utredning, men som trots allt har en ökad risk för prostatacancer,. 
Utöver detta beskriver avhandlingen hur stor andel av män i Stockholm som har genomgått 
vävnadsprovtagning och hur lång tid efter PSA provtagningen en sådan undersökning görs. 
Därtill undersöktes hur stor del av männen som drabbades av allvarliga infektioner till följd 
av vävnadsprovtagningen och huruvida denna typ av komplikationer har ökat under det 
senaste decenniet. 
10.1.1.1 Studie I 
Till följd av att det i en svensk studie visade sig att man kunde identifiera män med kraftigt 
förhöjd risk för prostatacancer baserat på deras familjehistoria, PSA och fem av männens 
egna basparsvariationer ville vi undersöka om dessa genetiska basparsvariationer kunde 
användas för att bättre identifiera vilka män som behöver genomgå utredning för misstänkt 
prostatacancer. I studien bjöds män yngre än 80 år in som hade genomgått en 
vävnadsprovtagning av prostata mellan år 2005 och 2007 vid två av tre laboratorier i 
Stockholm. Dessa män fyllde i en kort enkät och lämnade blodprover där deras genetiska 
basparsvariationer analyserades. För att samla information om männens tumörer hämtades 
information från det svenska cancerregistret och det nationella kvalitetsregistret för 
prostatacancer. Via de laboratorier som gör PSA-analyser kunde resultatet från dessa hämtas 
för varje enskild man och provtagningstillfälle, vilket också bildade basen i STHLM-0 (ett 
register över alla män i Stockholm som vid minst ett tillfälle sedan 2003 har gjort ett PSA 
test). 
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När den genetiska information lades till den ursprungliga modellen bestående av PSA, en 
variant på PSA(f/t PSA), ålder och familjehistoria förbättrades förutsägelsen om vilka av 
männen som hade prostatacancer. I en klinisk vardag innebär detta att doktorer bättre kan 
förutse vilka som behöver genomgå en vävnadsprovtagning av prostata. I studien visades att 
upp till 23 % av vävnadsprovtagningarna kunde undvikas utan att för många fall av allvarlig 
prostatacancer missades. 
10.1.1.2 Studie II 
Från en stor amerikansk studie är det känt att män med PSA strax under 3 ng/mL har lika stor 
risk för prostatacancer som män med PSA mellan 3 och 10 ng/mL. Ur detta perspektiv var 
syftet med studien att belysa huruvida genetiska basparsvariationer kan användas för att 
identifiera män med hög risk för prostatacancer trots låga PSA värden. Från en stor studie 
med 26 000 män i Stockholm som lämnat blod och fyllt i en enkät identifierades män med ett 
PSA mellan 1 och 3 ng/mL som inte hade någon känd prostatacancer, inte hade genomgått 
någon tidigare vävnadsprovtagning och var mellan 50 och 69 år. Sammanlagt bjöds 860 män, 
från tre olika riskgrupper baserat på deras genetiska riskpoäng, in till studien och 172 av 
dessa genomgick vävnadsprovtagning. Hos de med lägst risk hittades prostatacancer hos 18 
%, hos de med mellanrisk hittades cancer hos 28% och hos de med högst genetisk risk 
hittades prostatacancer hos 37%. Resultaten tolkades som att den genetiska profilen kan 
användas för att identifiera de män som har högst risk för prostatacancer trots att deras PSA 
värde är lågt.  
10.1.1.3 Studie III 
Utifrån kunskapen om att PSA testning är mycket vanligt i Stockholm undersöktes hur 
vanligt det är att män med förhöjda PSA värden genomgår vävnadsprovtagning av prostata. I 
en annan svensk studie är det visat att områden i Sverige där PSA testning är vanligt har lägre 
dödlighet i prostatacancer än områden där testning inte är lika vanligt. Dock är dödligheten i 
prostatacancer i de områden som har mest PSA testning fortfarande betydligt högre än i den 
europeiska screeningstudien för prostatacancer.  
Målet med studie 3 var att beskriva hur stor andel av männen i Stockholm som har genomgått 
vävnadsprovtagning av prostata och hur lång tid det tar från ett PSA test till ett vävnadsprov. 
Via de laboratorier som analyserar vävnadsprover från prostata identifierades män som 
mellan 2003 och 2012 genomgått dessa undersökningar. Via STHLM-0 kunde de PSA prov 
som låg till grund för vävnadsprovet identifieras och även de prov som låg före och efter i tid. 
Genom att länka männen till det nationella patientregistret kunde vävnadsprovtagningar från 
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andra typer av undersökningar och eller operationer sållas bort. För att kunna uttala sig om 
situationen i Stockholm och om hur män boendes i Stockholm utreds länkades männen också 
till befolkningsregistret varvid biopsier gjorda i Stockholm på stockholmare kunde sorteras 
fram. Vidare länkades dessa män till det svenska cancerregistret och det nationella 
kvalitetsregistret för prostatacancer.  
Sammanlagt görs nästan 4500 vävnadsprovtagningar av prostata via ändtarmen varje år i 
Stockholm. Nästan 15 % av alla män mellan 70 och 79 år har genomgått undersökningen. 
Nästan 10 % av männen mellan 60 och 69 samt 7 % av männen mellan 50 och 59 har 
genomgått undersökningen under 9 år före 2012.  
För män mellan 50 och 59 år med ett PSA värde mellan 4 och 10 ng/mL hade 42 % inte 
genomgått ett vävnadsprov inom ett år från det att de tog sitt PSA värde. För män mellan 60 
och 69 år låg andelen på 55 %. För män med ett PSA över 10 ng/mL hade 33 % av männen 
mellan 50-59 år och 42 % av männen mellan 60 och 69 år inte genomgått undersökningen 
inom ett år.  Detta var förvånansvärt höga siffror. Vad som händer med männen som inte 
genomgår utredningen är oklart, men en farhåga är att de inom några år kommer med 
symtom på obotbar prostatacancer. Detta exemplifierades även med en analys av just de män 
som diagnostiserades med en avancerad prostatacancer; det visade sig att nästan 13 % av 
dessa hade minst ett förhöjt PSA värde taget mer än 6 månader före sin diagnos. 
Studien belyser att en stor del av män i Stockholm har genomgått denna typ av undersökning. 
Ungefär hälften av männen har genomgått undersökningen utan att diagnostiseras med cancer 
vilket indikerar att en stor del av männen genomgår utredningen i onödan vilket i sin tur är ett 
bevis på PSAs dåliga träffsäkerhet. Utöver detta visade det sig också att det för mer än en 
tredjedel av män i åldrarna 50-59 år med kraftigt förhöjda PSA värden tar det längre tid än ett 
år innan de genomför en vävnadsprovtagning av prostata, om de överhuvudtaget genomför 
undersökningen.  
Uppenbarligen är viljan att ta PSA prov stor, men uppföljningen av förhöjda värden ter sig 
suboptimal. Att införa strukturerad uppföljning skulle kunna förbättra denna situation. 
10.1.1.4 Studie IV 
Det vanligaste sättet att diagnostisera prostatacancer är genom att ta vävnadsprover av 
prostata via ändtarmen med hjälp av ultraljud. Det är ett välkänt faktum att detta medför 
risker för blödning och infektioner. I en nyligen publicerad svensk artikel visades det att ca 6 
% av män med prostatacancer som genomgått en vävnadsprovtagning hämtar ut ett recept på 
urinvägsantibiotika inom 30 dagar efter provet. Andelen män som läggs in på sjukhus har 
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också ökat sedan år 2006. Flera internationella studier har påvisat en ökad frekvens i 
befolkningen av multiresistenta bakterier samt att andelen män som genomgår 
prostatapunktion drabbas av infektionsrelaterade komplikationer ökar över tid. Efter att i den 
kliniska vardagen ha noterat att ökningen av allvarliga infektioner också skedde i Stockholm 
gjordes denna studie för att bekräfta dessa farhågor och för att försöka få en förståelse till 
varför denna ökning har skett under de senaste tio åren. Den allvarligaste 
infektionskomplikationen till vävnadsprovtagning av prostata är blodförgiftning. Ett tecken 
på att en man drabbas av detta är hög feber och frossbrytningar. Vid dessa symtom brukar 
läkare genomföra en blododling för att kontrollera om bakterier finns i blodet eller inte. 
Genom att via register över genomgångna vävnadsprover och länkningar till ett flertal 
svenska hälsovårdsregister kunde 44047 genomgångna vävnadsprover identifieras mellan 
åren 2003 och 2012 hos 32196 män. Vid 620 tillfällen genomgick män en blododling inom 
30 dagar efter provtagningen. Vid 266 tillfällen växte det bakterier i blodet. I början av 
studieperioden genomgick 1 av 100 män en blododling inom 30 dagar, medan 1 av 50 män 
gjorde det i slutet av studieperioden. Andelen blododlingar där det växte bakterier ökade från 
0,38 % till 1,14 % under samma tidsperiod. Det visade sig att bakterier med nedsatt 
känslighet för vanliga antibiotika, som ges som förebyggande medicin vid 
vävnadsprovtagningen, ökade från 2003 till 2012. En teori till ökningen är att dessa 
resistensmekanismer är vanliga i länder dit svenskar ofta reser på semester, t.ex. Thailand, 
Egypten, Turkiet och övriga Sydostasien. En annan lanserad teori är att dessa 
resistensmekanismer ökar på grund av att det konsumeras för mycket antibiotika i onödan 
vilket leder till att bakterierna utvecklar denna okänslighet för antibiotika. Dock har Sverige 
haft en mycket positiv trend under de senaste åren då konsumtionen av dessa vanliga 
antibiotika har minskat med mellan 17 och 27 %. 
Sammanfattningsvis indikerar denna studie att de allvarliga komplikationerna har mer än 
fördubblats under de senaste tio åren. 
10.1.1.5 Slutsats 
I Stockholm görs 4500 vävnadsprover av prostata varje år. Nästan 1400 män diagnostiseras 
årligen med prostatacancer till följd av dessa undersökningar. Nästan 60 % av alla män har 
vid något tillfälle de senaste fem åren tagit ett PSA värde. Trots att PSA är ett vanligt 
blodprov, som de allra flesta läkare kommer i kontakt med, genomgår bara 67 % av männen i 
åldrarna 50-59 år en prostatapunktion inom ett år från deras PSA provtagning, trots ett relativt 
högt PSA. 
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Genom att utnyttja genetiska markörer kan man identifiera de män med låga värden som har 
hög risk för prostatacancer. De genetiska markörerna kan också användas för att identifiera 
en stor andel av de män med ett PSA mellan 4 och 10 ng/mL som inte behöver genomgå 
vävnadsprovtagning. Under senare år har de infektionsrelaterade komplikationerna efter 
vävnadsprovtagning ökat markant. Män som ändå behöver genomgå en prostatapunktion 
måste informeras om att mer än en av 50 män blir så pass sjuka att det anses motiverat att 
genomföra undersökning för att se om de drabbats av blodförgiftning. 
Genom att använda genetiska markörer och en strukturerad uppföljning kan antalet 
vävnadsprover minskas och därmed också antalet män som drabbas av allvarliga infektioner. 
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